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SUMMARY 
Summary 
T cell activation depends on the ability of the T cell receptor (TCR) to recognize specific 
antigens presented in the context of the major histocompatibility complex (MHC) on the antigen-
presenting cell (APC). The binding of the TCR to MHC promotes the formation of the immune 
synapse (IS). In this process, the TCR and its associated molecules localize to a central area of 
the T-cell-APC contact, the central supramolecular activating complex (cSMAC). Adhesion 
molecules relocate to the peripheral supramolecular activating complex (pSMAC). Essential 
proteins in this process are the Src family kinase members (Lck and Fyn). Lck phosphorylates the 
immunoreceptor tyrosine-based activation (ITAM) motifs of the TCR/CD3 complex leading to 
the recruitment of key molecules for the downstream signalling pathways and the IS formation.  
The formation of the IS also triggers changes in the tubulin cytoskeleton, including the 
translocation of the centrosome or microtubule (MT)-organizing centre (MTOC), to the IS, which 
is accompanied by the Golgi Apparatus, multivesicular bodies and mitochondria. These changes 
facilitate the polarized secretion of cytokines and exosomes toward the APC. MTOC polarization 
orchestrates active MT growth and forms the core of a dense MT network that regulates vesicular 
traffic at the IS.  
Aurora A is a serine/threonine kinase that plays a critical role in centrosome and spindle 
dynamics during mitosis. During centrosome maturation, Aurora A promotes MT assembly by 
recruiting nucleation and stabilization factors. Due to its role in controlling MT dynamics, we 
hypothesized that Aurora A may play a role in the activation of T lymphocytes during IS 
formation. We found that Aurora A is activated upon TCR stimulation and localizes at the IS 
during contact. Moreover, inhibition of Aurora A with pharmacological agents or genetic deletion 
in human or mouse T cells severely disrupts the dynamics of microtubules and CD3-bearing 
vesicles at the IS. Specific targeting of Aurora A impairs activation of the TCR/CD3 complex, 
preventing early T cell activation and downstream expression of CD69, CD25 and IL-2.  Aurora 
A inhibition causes delocalized clustering of Lck at the IS and decreases phosphorylation levels 
of tyrosine kinase Lck, thus indicating Aurora A is required for maintaining Lck active.  These 
findings establish Aurora A as a major regulator of early signaling and the tubulin cytoskeleton 
during T cell activation. 
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RESUMEN 
Resumen 
La activación de las células T depende de la capacidad del receptor de células T (TCR) 
para reconocer antígenos específicos en el contacto del complejo mayor de histocompatibilidad 
(MHC) de las células presentadoras de antígeno (APC). La unión del TCR al MHC promueve la 
formación de la sinapsis inmunológica (IS). En este proceso, el TCR y las moléculas que se 
asocian a él se localizan en el área central de la región de contacto entre la célula T y la APC, en 
lo que se conoce como el complejo de activación supramolecular central (cSMAC). Las moléculas 
de adhesión se trasladan al complejo de activación supramolecular periférico (pSMAC). Algunas 
de las proteínas esenciales en este proceso son los miembros de la familia de proteínas Src (Lck 
y Fyn). La proteína quinasa Lck fosforila los motivos de activación de inmunorreceptores basados 
en tirosina del complejo TCR/CD3 permitiendo el reclutamiento de moléculas esenciales para la 
ruta de activación del TCR y la formación de la IS.  La formación de la IS también induce cambios 
en el citoesqueleto de tubulina, incluyendo la translocación del centrosoma o el centro 
organizador de microtúbulos (MTOC), hacia la IS, acompañado por el aparato de Golgi, los 
cuerpos multivesiculares y las mitocondrias. Estos cambios facilitan la secreción polarizada de 
citoquinas y exosomas hacia la APC. La polarización del MTOC dirige el crecimiento activo de 
microtúbulos (MT), constituyendo el núcleo de una densa red de MT que regula el tráfico 
vesicular en la SI. 
La proteína Aurora A es una serina/treonina quinasa que desempeña un papel crítico en 
la dinámica del centrosoma y del huso mitótico durante la división celular. Durante la maduración 
del centrosoma, Aurora A promueve el ensamblaje de MT mediante el reclutamiento de factores 
nucleadores y estabilizadores de los mismos. Debido a su papel en el control de la dinámica de 
MT, postulamos que Aurora A podría ejercer un papel importante en la activación de células T 
durante la formación de la SI. Encontramos que Aurora A se activa tras la estimulación del TCR 
y se localiza en la IS durante el contacto celular. Por otro lado, tanto la inhibición farmacológica 
como la depleción génica de Aurora A en células T humanas o de ratón altera severamente la 
dinámica de MT así como el transporte a la IS de microvesículas que contienen CD3. El bloqueo 
de Aurora A impide la activación del complejo TCR/CD3, interrumpiendo la activación temprana 
de las células T así como la expresión de los genes CD69, CD25 y IL-2. La inhibición de Aurora 
A causa la deslocalización de tirosina quinasa Lck en la región de la SI y disminuye sus niveles 
de fosforilación, lo que indica que Aurora A es necesaria para mantener a Lck en su forma activa. 
Estos hallazgos demuestran que Aurora A es una molécula reguladora importante en la 
señalización temprana y del citoesqueleto de tubulina durante la activación de los linfocitos T. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Index 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1 
INDEX 
Agradecimientos 
Summary 
Resumen  
 
Index…………………………………………………………………................………………………..1 
List of abbreviations ...................................................................................... 5 
List of figures ................................................................................................ 9 
 
1. Introduction ........................................................................................... 13 
1.1 Immune and adaptive immunity ................................................................... 13 
1.2 ¿What is the immune synapse? .................................................................... 14 
1.3 T cell-APC contact: Initiating the IS ............................................................ 15 
1.4 Intracellular traffic of TCR/CD3, LAT and Lck .......................................... 18 
1.5 The centrosome as an organelle-organizing center ...................................... 20 
1.6 The Aurora family ........................................................................................ 24 
 
2. Objectives .............................................................................................. 29 
 
3. Materials and methods .......................................................................... 33 
3.1 Reagents and antibodies ............................................................................... 33 
3.2 Cells .............................................................................................................. 35 
3.3 Mice .............................................................................................................. 35 
3.4 Plasmids, siRNAs and transfection .............................................................. 36 
3.5 T cell activation ............................................................................................ 37 
3.5.1 Human TCR stimulation ........................................................................... 37 
3.5.2 Mouse TCR stimulation ............................................................................ 37 
3.5.3 Antigen stimulation ................................................................................... 37 
3.6 Cell lysis and immunoblotting ..................................................................... 37 
3.7 Cell conjugate formation, immunofluorescence and IS analysis. ................ 37 
3.8 Immunoprecipitation, mass spectrometry and analysis of phosphorylation 38 
3.9 Time-lapse confocal and total internal reflection fluorescence (TIRF) video 
microscopy. ............................................................................................................. 39 
3.10 Quantitative real-time PCR .......................................................................... 40 
  
2 
INDEX 
4. Results ................................................................................................... 43 
4.1 Localization of Aurora A at the IS ............................................................... 43 
4.2 Aurora A in MT dynamics and in MTOC translocation .............................. 45 
4.3 Aurora A in CD3ζ-bearing vesicles traffic at the IS .................................... 50 
4.4 Aurora A in TCR-driven actin dynamics ..................................................... 53 
4.5 Aurora A in early TCR signalling ................................................................ 55 
4.6 Mechanism through Lck regulation ............................................................. 62 
 
5. Discussion ............................................................................................. 69 
5.1 Aurora A localization and activation at the IS ............................................. 69 
5.2 Microtubule polymerization and vesicular traffic ........................................ 72 
5.3 Actin cytoskeleton ........................................................................................ 72 
5.4 Early T cell activation .................................................................................. 73 
5.4.1 Direct Lck regulation by Aurora A ........................................................... 74 
5.4.2 Lck indirect regulation by Aurora A ......................................................... 75 
 
6. Conclusions ........................................................................................... 81 
 
7. Conclusiones ......................................................................................... 85 
 
8. References ............................................................................................. 89 
 
9. Annexes ............................................................................................... 103 
9.1 Supplementary information ........................................................................ 103 
9.2 Publications related to this Thesis work ..................................................... 106 
9.3 Other publications ...................................................................................... 107 
 
Annexe I………………………………………………………………..……………………….…..111 
 
 
  
 
 
  
 
 
 
 
 
List of abbreviations 
 
 
 
 
 
  
 
 
 
 5 
LIST OF ABBREVIATIONS 
List of abbreviations 
 
ACD: Asymmetric Cell Division 
ADAP: Adhesion and Degranulation-
promoting Adapter Protein 
APC: Antigen Presenting Cell  
BSA: Bovine Serum Albumin 
BF: Bright Field 
CaM: calmodulin 
Cbp: Csk Binding Protein  
Csk: C terminal Src Kinase 
CDC42: Cell Division Cycle 42 
CRAC: Ca2+ release-activated channels 
cSMAC: central Supramolecular Activation 
Cluster  
D-box: Destruction box 
DMSO: Dimethyl Sulfoxide 
DC: Dendritic Cell 
EB: End-Binding protein  
ERK: Extracellular signal-Regulated 
Kinase 
GA: Golgi Apparatus 
GFP: Green Fluorescence Protein  
GM-CSF: Granulocyte Macrophage 
Colony-Stimulating Factor 
G418: Geneticin 
HA: Hemagglutinin 
HDAC6: Histone Deacetylase 6  
ICAM: Intercellular Adhesion Molecule 
ITAM: Immunoreceptor Tyrosine-based 
Activation motifs  
Ig: Immunoglobulin 
IFN: Interferon 
IFT: Intraflagellar Transport 
IL: Interleukin 
IP3: 1,4,5-triphosphate 
IS: Immunological Synapse 
kDa: KiloDalton 
LAT: Linker of activated T cells 
Lck: Lymphocyte-specific protein tyrosine 
kinase  
LPS: Lipopolysaccharide 
mAb: Monoclonal Antibody 
MAPK: Mitogen-Activated Protein 
Kinases 
MAL: Myelin And Lymphocyte protein  
MHC: Major Histocompatibility Complex  
MT: Microtubule 
MTOC: Microtubule-Organizing Center  
OVA: Ovalbumin 
PAG: Phosphoprotein Associated with 
Glycosphingolipid-enriched microdomains  
PBLs: Peripheral Blood Lymphocytes  
PBMCs: Peripheral Blood Mononuclear 
Cells 
PBS: Phosphate Buffered Saline  
PCM: Pericentriolar Matrix 
PIP2: Phosphatidylinositol-4,5-
bisphosphate 
PKC: Protein Kinase C  
PLCγ1: Phospholipase C, gamma 1  
Plk-1: Polo-like Kinase 1 
pSMAC: peripheral Supramolecular 
Activation Cluster  
SEB: Superantígeno B 
SEE: Superantígeno E 
SFK: Src Family Kinase  
siRNA: small interfering RNA 
TACC: transforming acidic-coiled-coil 
TCR: T Cell Receptor  
TIRFm: Total Internal Reflection 
Fluorescence microscopy 
TGN: Trans-Golgi Network 
Unc-119: Uncoordinated 119 
VCAM: Vascular Cell Adhesion Molecule 
VLA: Very Late Antigen  
WASp: Wiskott–Aldrich syndrome protein 
and SCAR homologue 
WB: Western Blot 
WT: Wild Type  
ZAP70: ζ chain-associated protein kinase 
70 
γ-TURC: γ-Tubulin Ring Complex 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
List of figures 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9 
LIST OF FIGURES 
List of figures 
 
Introduction 
Figure I1. Different components of the immune system………………………………………….………..13 
Figure I2. Diagram of the IS in the contact area between a T cell and an APC……………………..............14 
Figure I3. Membrane microdomains in T cell activation…………………………………………..……….17 
Figure I4. Intracellular traffic and activation at the IS……………………………………………..……….20 
Figure I5. Centrosome translocation and docking at the IS………………………………………..……….23 
Figure I6. Structure and domains of the Aurora kinases family…………………………………..………..24 
Figure I7. Regulation of mitotic entry by Aurora A………………………………………………..………25 
Figure I8. Control of MT stability by Aurora A……………………………………………………..……..26 
 
Results 
Figure R1. Aurora A is located at the IS contact area and is activated upon TCR triggering……….…..….43 
Figure R2. Specific silencing of Aurora A…………………………………………………………….…...44 
Figure R3. Active Aurora A is located at the IS in mouse CD4+ T cells……………………………..…….44 
Figure R4. Both Aurora A-GFP and active Aurora A localize at the IS……………………………...……..45 
Figure R5. Microtubule dynamics at the IS is impaired by Aurora A chemical inhibition…………..….….46 
Figure R6. Aurora A gene ablation impairs EB3 incorporation in MT +TIPs………………….…….…….47 
Figure R7. Aurora A gene ablation impairs MT dynamics at the IS…………………….………….….…...48 
Figure R8. Aurora A inhibition does not affect MTOC translocation to the IS…………………….….…...49 
Figure R9. Aurora A gene ablation does not affect the MTOC translocation to the IS………………..…...50 
Figure R10. Aurora A blockade does not affect the percentage of conjugate formation……..……….…...50 
 Figure R11. Accumulation of TCR/CD3ε at the IS is not affected by Aurora A inhibition ……….……..51 
R12. Trafficking of CD3-bearing vesicles at the IS is impaired by Aurora A chemical inhibition or gene 
ablation…………………………………………………………………………………………………….52 
Figure R13. Aurora A inhibition does not affect actin cytoskeleton dynamics………………………….....53 
Figure R14. Actin spreading and distribution during the IS is not affected by Aurora A inhibition….…...54 
Figure R15. Inhibition of Aurora A does not affect actin accumulation at the IS……………….………...55 
Figure R16. Aurora A inhibition impairs TCR signaling pathways in Jurkat T cells……………………...56 
Figure R17 Aurora A inhibition impairs TCR signaling pathways in primary CD4+ T cells…………….…56 
 10 
LIST OF FIGURES 
Figure R18. Aurora A inhibition impairs TCR signaling in a MHC/peptide-specific system….….……….57 
Figure R19. Dose-response effect of the Aurora A inhibitor MLN8237 on T cell activation…….……….58 
Figure R20. Addition of MLN8237 just before T cell activation impairs TCR signaling……….………...58 
Figure R21. MLN8237 is a reversible inhibitor………………………………………………….………...59 
Figure R22. TCR signaling is not affected by Aurora B inhibition……………………………….…….…59 
Figure R23. TCR signaling is impaired by silencing of Aurora A……………………………….………..60 
Figure R24. IL2, CD69 and CD25 expression is impaired by Aurora A inhibition……….………………60 
Figure R25. Aurora A inhibition impairs TCR signaling in mouse CD4+ T cells…………….…………...61 
Figure R26. Aurora A gene ablation blocks TCR signaling pathways……………………….……………61 
Figure R27. Overexpression of Aurora A increases levels of  TCR molecules phosphorylation  .………..62 
Figure R28. Aurora controls localization and phosphorylation of the tyrosine kinase Lck……….……….63 
Figure R29. Membrane Lck is affected by Aurora A inhibition……………………………….…………..64 
Figure R30. Lck phosphorylation at Y394 decreases by Aurora A inhibition…………………..………….64 
Figure R31. Aurora A keeps Lck phosphorylated before TCR stimulation…………………….………….65 
 
Discussion 
Figure D1. Activation of Aurora A during the IS by proteins from GA……………………….….………..71 
Figure D2.  Lck direct regulation by Aurora A…………………………………………………..…………75 
Figure D3. Lck indirect regulation by Aurora A…………………………………………………..………77 
 
 
 
 
 
  
 
 
 
 
 
 
 
Introduction 
 
 
 
 
 
 
 
  
 
 
 13 
 
INTRODUCTION 
1. Introduction  
 
1.1 Immune and adaptive immunity 
 
Immune responses protect the organism against infections through cell- and molecular- based 
mechanisms. These mechanisms are subdivided in two arms of the immune response: innate and adaptive. 
Both responses are executed by cells of different linages and are interdependent. Innate immune system 
acts providing immediate defence against pathogens by recognizing and responding to them in a generic 
way. Innate immune system activates the adaptive immune system through the process known as antigen 
presentation. Adaptive immunity is a highly specialized system, composed by several cell types and 
complex processes. This mechanism allows to respond to a specific pathogen, generating immunological 
memory for future infections. The axis of the adaptive immune response resides in lymphocytes. B 
lymphocytes are responsible for humoral immunity, providing defense through secretion of antibodies. By 
contrast, T lymphocytes are involved in cell-mediated immunity. There are two different population of T 
lymphocytes, cytotoxic CD8+ and helper CD4+ T lymphocytes.  CD8+ lymphocytes are involved in 
eliminating cells producing foreign antigens, such as virus-infected cells and other intracellular 
microorganisms. By contrast, the CD4+ T lymphocytes provide an important link between adaptive 
immunity and effectors of innate immunity mechanisms, promoting the proliferation and differentiation of 
other lymphocytes and activating and recruiting cells of the innate immune response (Fig. I1).  
 
 
 
 
 
 
 
 
 
 
Figure I1. Different components of the immune system. The innate immune response is the first 
line of defence against infection. It is composed by several cellular components such as dendritic cells, 
mast cells, macrophages, natural killer cells and granulocytes (basophils, eosinophils and neutrophils) 
and soluble factors including complement proteins. The adaptive immune response acts later but in a 
specific way. It is composed by B lymphocytes that produce antibodies, and CD4+ and CD8+ T 
lymphocytes that carry out the cellular response. Natural killer T cells and γδ T cells are cytotoxic 
lymphocytes that are in the middle of innate and adaptive immunity (Dranoff, 2004). 
 14 
 
INTRODUCTION 
1.2 ¿What is the immune synapse? 
 
The contact between the T cell and the antigen presenting cell (APC) is termed the immune synapse 
(IS) and this structure acts as a transient, cell-to-cell communication structure between the T cell and the 
APC, which is a hallmark of the adaptive immune response (Monks et al, 1998). This intimate contact 
promotes the proliferation and differentiation of the lymphocytes involved in the contact.  The first 
encounter of a T lymphocyte with an antigen bearing sufficient affinity for its T cell receptor (TCR) to 
trigger its activation takes place at lymph nodes that drain most peripheral tissues. It depends on the 
interaction of the T cell with an APC that presents the antigen associated to its major histocompatibility 
complex (MHC) molecules. APCs can be myeloid cells, such as dendritic cells or macrophages; lymphoid, 
e.g. B lymphocytes, or non-immune cells, such as target cells that have been infected by virus or bacteria 
or are transformed into tumorigenic cells, activated endothelial cells and some others (Friedl et al, 2005). T 
cells scan the surface of the APC and if the affinity of the TCR for the peptide-MHC complex is sufficient, 
the TCR undergoes conformational changes that activate different signaling pathways, leading to 
cytoskeletal reorganization and organelle polarization to the contact area with the APC. The stability of the 
IS is sustained by the TCR-dependent transactivation of adhesion molecules, e.g. integrins, which maintain 
the IS over time and seal the extracellular space between the T cell and the APC. In this manner, the T:APC 
space adopts cleft shape, not unlike those observed in neuronal synapses. The IS structure is classically 
described as an eye-shaped molecular assembly. It is formed by a central SMAC (cSMAC; supramolecular 
activation clusters) that contains TCR with associated molecules (TCR signalosomes). The cSMAC is 
surrounded by the peripheral SMAC (pSMAC), which comprises adhesion molecules such as integrins 
(Davis & van der Merwe, 2006). Moreover, the distal SMAC (dSAMC) is enriched with proteins with large 
extracellular domains such as phosphatases that may have an inhibitory role during the IS formation (Davis 
& Dustin, 2004). This structure establishes an intimate contact between the T cell and the APC that increases 
the relative concentration of secreted molecules, thereby facilitating the exchange of signals between them 
(Fig. I2). 
 
 
 
 
 
Figure I2. Diagram of the IS in the contact area between a T cell and an APC. (a) T cell activation 
promotes the segregation of different molecules in the contact area between both cells during the IS 
formation. (b) Diagram showing the ‘bull's eye’ pattern of several distinct concentric domains, which 
are known as supramolecular activation clusters (SMACs). The cSMAC (central, pink) is enriched 
with TCR microclusters, co-stimulatory receptors and protein-tyrosine kinases. The pSMAC 
(peripheral, green) contains integrins, such as LFA-1 and its ligand ICAM1, and cytoskeletal linker 
protein. The dSMAC (distal, grey) includes protein-tyrosine phosphatase CD45 and glycoproteins 
CD44 and CD43 (Yu et al, 2013). 
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1.3 T cell-APC contact: Initiating the IS 
 
The formation of the IS involves that the membrane of the T cell and that of the APC are in close 
proximity to each other. The plasma membrane is not entirely homogeneous; separate domains can be 
defined according to their different composition of lipids and proteins (Brown, 1998). In terms of lipids, 
the plasma membrane is formed by different specific domains distinguished by their solubility or 
insolubility in non-ionic detergents. Insoluble, cholesterol-rich microdomains are classically termed ‘rafts’ 
(Simons & Ikonen, 1997). Since different adaptors and signaling intermediates display a preference for 
localizing in raft or non-raft domains, lipid-based regions can be considered as platforms for signaling 
molecules involved in T cell activation. In this view, these platforms boost, or block signaling; and these 
signals are coordinated by the action of different lipid-associated proteins that are the backbone of these 
specific microdomains. The coalescence of specialized membrane microdomains at the IS requires the 
dynamic rearrangement of the actin and tubulin cytoskeletons. Both cytoskeletal systems are heavily 
involved in the movement and segregation of membrane and intracellular components. For example, they 
participate in the accumulation of the TCR at the IS that accounts for a higher clustering of the TCR than 
that predicted by models of passive diffusion. In this regard, passive lateral diffusion of receptors is actin-
dependent. A model of actin-dependent TCR accumulation envisions the pSMAC as a contractile actin-
myosin ring that allows retrograde flow of actin and centripetal movements that direct the TCR/CD3 
nanoclusters to the center of the IS (Ilani et al, 2009). Nanoclusters merge into microclusters before reaching 
the cSMAC (Lillemeier et al, 2010; Varma et al, 2006).  
A proposed model is that TCR/CD3 is translocated into specific cholesterol-enriched microdomains, 
where it is activated by Lck (He & Marguet, 2008; Swamy et al, 2016). CD28, a major co-stimulation 
receptor that binds to CD80 and CD86 also concentrates at the cSMAC, controlling the ability of PKCθ to 
activate transcription factors, e.g. NF-κB (Yokosuka et al., 2010).  
The cognate recognition of peptide-MHC (p-MHC) by the αβTCR subunits of the TCR-CD3 complex 
promotes a conformational change in the heterodimers containing the CD3ε subunit (CD3 γε and δε) prior 
to the phosphorylation on its own immunoreceptor tyrosine-based activation motif (ITAM) and the three 
ITAMs at each CD3ζ subunit of the homodimers that are part of the CD3 complex (Figure I3). Nck is 
rapidly recruited to the TCR/CD3 complex upon exposure of a proline-rich, Nck-binding sequence (PRS) 
in CD3ε. Nck then binds to the adaptor protein Src homology 2 (SH2) domain-containing leukocyte protein 
of 76 kD (SLP76) and Vav, which in turn promotes the re-organization of the actin cytoskeleton (Gil et al, 
2002). In addition to this conformational change, ITAM phosphorylation by the Src-family kinase Lck 
and/or Fyn enables the recruitment of proteins containing SH2 domains, such as ZAP70. CD3 and ZAP70 
coupling predates the recruitment of CD4 or CD8 co-receptors, which are bound to Lck. CD4 or CD8 
remain in close proximity to the TCR-CD3 complex, enabling lateral binding to the corresponding MHC 
(CD4-MHCII; CD8-MHCI). This interaction stabilizes the TCR-p-MHC interaction, while Lck keeps 
phosphorylating ITAMs that are being recruited to the macromolecular complex (Gascoigne et al, 2011). 
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Active ZAP70 phosphorylates LAT, which is a scaffold protein bearing multiple tyrosine residues. 
Phosphorylated LAT acts as docking site for different proteins. LAT forms two spatially segregated pools; 
one appears at the plasma membrane and it is involved in the amplification of the initial TCR signal. A 
second pool localizes to intracellular compartments (Bonello et al, 2004). LAT interacts with SLP76, which 
recruits multimolecular complexes that converge on the cytoskeletal regulators CDC42/Rac, Nck and Vav, 
thereby controlling the remodeling of T cell actin cytoskeleton (Martin-Cofreces et al, 2014; Pauker et al, 
2012) (Fig. I3)). One molecule of these complexes is PLCγ1, which binds to LAT at phospho-Y132 and 
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to produce inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG). DAG is an activator of different PKCs (serine/threonine kinases) while IP3 causes 
a sustained increase in intracellular Ca2+ concentrations from endogenous reservoirs, which is crucial for 
NFAT activation (Balagopalan et al, 2010). Production of DAG is a critical step for the propagation of 
signals emanating from the TCR and centrosome polarization to the IS (Quann et al, 2009). 
DAG binds to and activates PKD2. PKD2 also requires PKC-dependent phosphorylation on S707 and 
S711 for its complete activation. This process promotes the amplification of PKC and PKD2 activation and 
mediates the production of cytokines that stimulate T cell proliferation and T cell-dependent inflammation, 
such as interleukin 2 (IL-2) and interferon gamma (IFNγ), respectively (Navarro et al, 2012). Additionally, 
DAG participates in the activation of Ras through binding to the serine/threonine kinase Raf-1. Ras 
activation initiates the mitogen-activated protein kinases signaling cascade (MAPK). This results in the 
phosphorylation and activation of the serine/threonine kinases ERK1 and ERK2, which in turn 
phosphorylate and activate transcription factors, e.g. ELK-1, SAP-1 and SAP-2. As a result, ERK1 and 2 
regulate the expression of early activation genes such as c-Fos and c-Jun in T cells. Furthermore, ERK1 and 
2 also play a role in microtubule (MT) remodeling through the regulation and phosphorylation of stathmin 
(Filbert et al, 2012). RSK (Ribosomal S6 kinase) is also regulated by ERK1 and 2, promoting cell cycle 
progression and cytokine production in T cells. Finally, other proteins regulated by the ERK1/2 pathway 
are MNK1 and MNK2, which participate in the phosphorylation of the eukaryotic translation initiation 
factor eIF4E (Navarro & Cantrell, 2014; Romeo et al, 2012) (Fig. I3)). 
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Figure I3. Membrane microdomains in T cell activation. TCR-activation pathways. Upon TCR 
recognition of a peptide-charged MHC, the TCR/CD3 complex undergoes conformational changes 
(not depicted). These conformational changes initiate its activation, allowing Nck binding to CD3ε 
and actin polymerization. TCR/CD3 conformational changes also favor the phosphorylation of the 
intracellular ITAMS of the CD3ε and CD3ζ subunits by Lck. Phosphorylated ITAMs are docking 
sites for the SH2 domains of ZAP70, which accumulates at the TCR/CD3 complexes and 
phosphorylates LAT in different tyrosine residues. LAT acts as a signaling amplifying platform, 
where PLCγ clusters and activates. PLCγ generates second messengers for TCR signaling, like IP3 
and DAG from PIP2. IP3 activates calcium intracellular flux. DAG helps to the activation of different 
signaling mediators such as PKC and Ras, to trigger PKD2 and MAPK signaling cascades to induce 
the expression of late activation genes like IL-2. Nck and LAT act in concert to recruit SLP76, Vav, 
Cdc42 and Rac1, to reorganize actin cytoskeleton at the IS. 
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1.4 Intracellular traffic of TCR/CD3, LAT and Lck 
 
The concentration of TCR/CD3 complexes at the IS comes from two sources. One is lateral membrane 
mobility. The other is the recycling of the complexes via endosomes (Figure I4). In general, the endosomal 
system is used by the cells to maintain a metabolic steady-state, enabling the rapid reutilization of pre-
synthesized molecules. Endosomes are characterized by the localization of different Rab GTPases bound 
to their membrane, e.g. Rab11. These molecular switches act as spatial and temporal coordinators of 
recycling (Baetz & Goldenring, 2013). Endosomes also contain signaling molecules and adaptor proteins. 
Finally, they are essential for plasma membrane replenishment at the IS. This is a crucially important event, 
because the interaction between the T cell and the APC through the IS continuously triggers TCR/CD3 
internalization. However, for sustained signaling to take place, the amount of TCR/CD3 complexes at the 
T cell surface of the IS need to be relatively constant (Varma et al, 2006), hence the internalized fraction 
needs to be renewed immediately (Das et al, 2002). Not surprisingly, the endosomal TCR/CD3 pool 
constitutes an important fraction of the total amount of TCR/CD3 that is recycled back to the IS (Fig. I4). 
The amount of internalization/recycling events at the IS functionally results in heavy and localized vesicular 
trafficking, leading to the definition of the IS as a focal point of endocytosis/exocytosis. 
Although actin dynamics may contribute to TCR/CD3 complex concentration at the IS, mainly due to 
retrograde flow (Beemiller et al, 2012), the recycling pool is mostly driven by MT and MT-based motors. 
Moreover, dynein, a minus-end directed MT motor protein, accumulates at the pSMAC, where it associates 
with ADAP (Adhesion and Degranulation promoting Adaptor Protein). This interaction may generate the 
pulling force needed to polarize the centrosome to the IS (Combs et al., 2006). This can be graphically 
described as “reeling a fish”, in which the dynein-ADAP complex acts as a fixed reel, the MTs would be 
the line and the centrosome would be the fish. However, dynein/dynactin activity was also found essential 
for sustained T cell activation, which likely means that dynein is not only involved in the reeling of the 
centrosome, but also in its long-term maintenance in the contact zone (Hashimoto-Tane et al, 2011; Martin-
Cofreces et al, 2008). 
On the signaling front, continuous internalization and recycling of TCR/CD3 depends on the 
phosphorylation of a di-leucine motif present on the CD3γ chain mediated by PKC, which is then recruited 
by the clathrin adaptor protein AP-2 (Monjas et al, 2004). TCR/CD3 complexes that enter this pathway are 
directed to recycling endosomes positive for Rab4 and Rab11. Rab4-endosomes are early endosomes 
involved in the rapid shuttling of internalized receptors to the plasma membrane in a MT-independent 
manner. On the other hand, endosomes marked by Rab11 aggregate in more distal locations inside the cell, 
following a slower route and moving along the MT in order to return to the plasma membrane. Other Rab 
GTPases, e.g. Rab35, are also involved in the regulation of endosomal trafficking as well as in actin 
polymerization through WASp (Wiskott–Aldrich syndrome protein and SCAR homologue). WASp 
activates Arp2/3 complex and also interacts with tubulin cytoskeleton in both early and late endosomes, 
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conjoining both networks to promote efficient endosome shuttling back to the IS (Finetti et al, 2015) (Fig. 
I4).  
TCR/CD3-containing endosomes can also be degraded by fusion with lysosomes (endolysosomal 
system). This is important to modulate TCR-dependent signaling. TCR/CD3 internalization and subsequent 
degradation requires a TCR ligand, and it also involves Lck and ZAP-70. Lck is also implicated in a 
constitutive TCR internalization by phosphorylating clathrin heavy chain (Crotzer et al, 2004). Despite 
these data, there is also evidence of tyrosine kinase-independent TCR internalization and downregulation.  
Regarding the type of membrane-dependent mechanism involved in TCR/CD3 internalization, it has 
been proposed that non-engaged, bystander TCRs are internalized in clathrin-coated pits, while engaged 
TCRs are internalized in a cholesterol-enriched domains-dependent manner (Monjas et al, 2004). More 
recently, GPCR-interacting β-arrestin-1, which is a multiple-subunit receptor without intrinsic enzymatic 
activity, has been identified as a new ligand that can bind to phosphorylated ITAMs. This fact places 
TCR/CD3 complexes also in the GPCRs-driven, arrestin-dependent internalization pathway. TCR/CD3 
ligation promotes its PKC-dependent phosphorylation at S163, which in turn promotes β-arrestin-1 
recruitment. In this manner, bystander, co-internalized TCRs are directly recycled back to the plasma 
membrane, while engaged, internalized TCRs are targeted to lysosomes for degradation (Fernandez-Arenas 
et al, 2014). 
In contrast to TCR/CD3 vesicles, which are controlled by VAMP3, the endosomal recruitment and 
docking of LAT to the cortical region of the IS depend of the v-SNARE protein VAMP7. It is, however, 
important to note that CD3 vesicles may also interact with VAMP7. Endosomal pools of LAT are localized 
in different subpopulations of recycling endosomes positive for Rab27 and Rab37 (Fig. I4). The main 
difference between CD3- and LAT-containing vesicles is that LAT vesicles do not fuse with the plasma 
membrane. This suggests that early phosphorylation of LAT upon TCR activation depends on the clustering 
of the LAT pool at the plasma membrane, rather than on the LAT subset at endosomes. The latter pool is 
likely more important to stabilize signaling mediators close to the TCR (Larghi et al, 2013; Soares et al, 
2013a). Analysis of end-binding protein 1 (EB1) by TIRFm (total internal reflection fluorescence 
microscopy) showed that MT growing mediated by EB1 favors the movement of cortical vesicles 
underneath the TCR/CD3 microclusters at the plasma membrane. EB1 also favors the proximity of LAT- 
and TCR/CD3-harbouring vesicles at the IS, thereby facilitating the sustained activation of LAT and PLCγ1 
upon TCR triggering (Martin-Cofreces et al, 2012). Moreover, a Rab11b- and MAL-positive endosomal 
pool containing Lck also contributes to T cell activation. In this pool, MAL enables the association of Lck 
to the plasma membrane at the IS, whereas Rab11b interacts with myosin 5B through the adaptor protein 
uncoordinated 119 (Unc-119), promoting the movement of the vesicles from the peri-centrosomal region 
to the IS (Martin-Cofreces et al, 2014; Soares et al, 2013b) (Fig. I4)).  
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1.5 The centrosome as an organelle-organizing center  
 
In different immune cell types, cytoskeletal remodeling underlies functional polarization. This process 
is important for many highly specialized and polarized cells, such as the neurons, in which the localization 
of the centrosome determines the number of neurites that initially sprout from the cell body, and which of 
Figure I4. Intracellular traffic and activation at the IS. TCR recycling is important for a sustained 
T cell signalling. TCR complex is endocytosed by the formation of Rab4- and Rab11-bearing 
vesicles. They are transported along the MTs towards the MTOC or centrosome. Once in the 
proximity of the IS they fuse in a VAMP3-dependent manner. Lck and LAT also have an intracellular 
pool that docks at the IS. Lck vesicles are transported in a myosin II-dependent manner in vesicles 
bearing Rab11b and Unc119, and its release to the plasma membrane depends on MAL protein. LAT 
vesicles, marked with Rab27 and Rab37, move to the subcortical region and its accumulation and 
dynamics there depend on their interaction with EB1 and the tubulin cytoskeleton.  
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these becomes the axon (de Anda et al, 2005). Microtubule-organizing centre (MTOC) reorientation also 
promotes the movement of other cellular organelles such as the Golgi Apparatus (GA), the mitochondria 
and the recycling and secretory apparatus. These events also occur in T cells in response to antigen 
recognition by the TCR. TCR triggering in a polarized, migrating T cell trumps migratory polarity, and the 
leading edge evolves into a structure containing radially symmetric lamellipodium that spreads over the 
APC (Dustin et al, 2010). The MTOC relocates to the cSMAC, along with many other cellular components 
and organelles (Huse et al, 2008). MTOC polarization promotes a directional secretion of cytokines and 
vesicles towards the APC, which is very important for the specificity of the CD4+ T cell-dependent response 
(Mittelbrunn et al, 2011). Moreover, MTOC translocation is crucial for the function of cytotoxic T 
lymphocytes and NK cells, enabling the polarized secretion of granules containing perforin, granzymes and 
cathepsins that kill target cells (Stinchcombe & Griffiths, 2007). 
The Src family of Tyr-kinase proteins, e.g. Lck, is involved in centrosome translocation and docking to 
the membrane upon TCR activation. An early study demonstrates that Lck-dependent ITAM 
phosphorylation in the TCR/CD3 complex was essential for centrosome polarization (Lowin-Kropf et al, 
1998). However, later evidence shows that Lck-deficient cells do polarize the centrosome around the 
nucleus, but cannot maintain the centrosome at the IS, suggesting that this protein is not involved in 
centrosome translocation per se, but it participates in its stabilization at the IS (Tsun et al, 2011). On the 
other hand, Fyn-deficient cells do not polarize the centrosome properly; interestingly, Fyn does not 
compensate the lack of Lck, which indicates that both proteins are important for centrosome translocation 
and docking (Martin-Cofreces et al, 2006).  
Another important factor is DAG (Figure I5). DAG is produced by PLCγ1 at the IS during its formation, 
promoting the recruitment of several proteins containing DAG-binding C1 domains to the plasma 
membrane. MTOC polarization is preceded by accumulation of DAG at activated TCR microclusters, 
suggesting that DAG guides centrosome positioning. Indeed, the absence of DAG blocks centrosome 
translocation (Huse, 2012). T cells likely use both DAG and PIP3 to decouple lamellipodial dynamics from 
centrosome movement. The clustering of DAG and PIP3 conversion by lipid phosphatases may be 
important for the transition between migratory and synaptic morphologies (Huse, 2012). Some of the DAG-
binding proteins are members of PKC family, which are involved in many TCR-induced responses such as 
proliferation and secretion of cytokines (Baier & Wagner, 2009). There is an early accumulation of PKCε 
and PKCη at the IS, which is followed by the subsequent accumulation of PKCθ at the peripheral actin ring 
and the polarization of the centrosome (Quann et al, 2011). The differences in the timing of recruitment of 
these proteins can be explained by their affinities for DAG; PKCε and PKCη bind to DAG with higher 
affinity than PKCθ (Huse et al, 2013). Therefore, affinity for DAG and the interaction with other lipid or 
proteins could potentially tune the localization of different PKCs. 
On the other hand, accumulation of DAG at the IS engages the MT-based dynein motor complex 
(Quann et al, 2009). Dynein is a multisubunit protein composed by two heavy chains that contain the motor 
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and MT binding domains and several accessory light chains that provide structural integrity and support 
interactions with other proteins. One of these interacting proteins is dynactin, a multi-subunit complex that 
enhances dynein processivity and controls its localization (Fu & Holzbaur, 2014; Kikkawa, 2013). The 
recruitment of SLP-76 and ADAP into the integrin ring at the pSMAC facilitates dynein movement to the 
IS (Combs et al, 2006). The dynein/dynactin complex is involved in the polarization of the MTOC to the 
IS in human T cells (Fig. I5). Disruption of dynein/dynactin complex prevents the correct localization of 
the centrosome (Martin-Cofreces et al, 2008), while ADAP depletion prevents both dynein accumulation 
and MTOC translocation (Combs et al, 2006). ADAP interacts with MTs and also with dynein, suggesting 
that accumulation of ADAP at the pSMAC generates tension along MTs that support the MTOC reeling 
mechanism toward the IS (Combs et al, 2006). This suggests that dynein/dynactin complex may help dock 
the MTOC to the IS by interacting with Fyb/ADAP (Martin-Cofreces et al, 2014) (Fig. I5). However, in 
mouse primary T cells, depletion or inhibition, of dynein is not enough to block the translocation of the 
MTOC; although it slows the dynamics of TCR/CD3 microclusters (Hashimoto-Tane et al, 2011). These 
results suggest that a dynein-independent pathway may also mediate MTOC reorientation; or that these 
mechanisms differ from human to mouse lymphocytes.  
Coupling between actin and MT networks seems essential for MTOC translocation (Martin-Cofreces 
et al, 2011; Obino et al, 2016). Several proteins involved in coupling MT and actin cytoskeletons include 
the scaffolding molecule IQGAP1 and the Diaphanous formins. These molecules do participate in MTOC 
polarization (Gomez et al, 2007). A proposed model suggests that dynein may pull the MT cytoskeleton, 
while myosin II may push it from behind, although the role of myosin II still remains unclear (Liu et al, 
2013). Therefore, much work is still needed to elucidate the cross-talk between actin and tubulin-based 
motors in MTOC polarization. 
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Figure I5. Centrosome translocation and docking at the IS. (a) Contact between the APC and T 
cell triggers a rapid translocation of the MTOC towards the IS (2-5 min). Migrating lymphocytes 
show a polarized shape. Cognate contact with a specific APC promotes clustering of TCR/CD3 
complexes and production of local DAG. PKCε and η cluster to DAG and helps actin polymerization. 
PKCθ clusters to actin cytoskeleton and regulates its dynamics. Dynein/dynactin complexes and 
Myosin IIA helps the coalescence of TCR/CD3 microcluster and MTOC translocation to the IS in 
formation. (b) Activation of TCR/CD3 through the phosphorylation of the ITAMs by Lck and Fyn 
members of src family of kinases promotes MTOC translocation to the IS.  This movement depends 
on the dynein/dynactin complex and also requires the interaction of ADAP with the integrins to 
generate the pulling force towards the IS.  
 
 24 
 
INTRODUCTION 
1.6 The Aurora family 
 
The Aurora family of serine/threonine kinases comprises three members in humans—Aurora A, B and 
C—which are encoded by three different genes (Carmena & Earnshaw, 2003) and are key regulators of 
different mitotic processes (Barr & Gergely, 2007). Auroras contain a specific aurora kinase domain with 
a regulatory threonine residue in the activation loop, which phosphorylation promotes kinase activation. 
Auroras also present a D-box domain (destruction box), which mediates their proteasome-dependent 
degradation and a N-terminal regulatory domain involved in substrate binding and subcellular location 
(Lukasiewicz & Lingle, 2009) (Fig. I6). Aurora A plays a critical role for proper cell cycle progression and 
in centrosome and spindle dynamics during mitosis, whereas Aurora B regulates the kinetochore attachment 
to the MTs and cytokinesis (Hochegger et al, 2013). Aurora C is the least studied member of the family and 
seems to have a role during meiosis (Yang et al, 2015). 
 
Aurora A is self-activated by autophosphorylation at T288 in its T loop, helped by cofactors including 
Bora, TPX2, Ajuba and PAK1 (Barr & Gergely, 2007; Bischoff et al, 1998; Gopalan et al, 1997). The 
mechanism of activation by cofactors is well established in case of TPX2. TPX2 induces the 
autophosphorylation of Aurora A but also prevents dephosphorylation of the activating residue by the 
protein phosphatase PP1 (Bayliss et al, 2003). Moreover, TPX2 targets Aurora A to the mitotic spindle MTs 
for assembly and maintenance of the mitotic spindle (Kufer et al, 2002). Polo-like kinase 1 (Plk-1) and 
CDK11 are also involved in Targeting of Aurora A to the centrosomes for their proper maturation (Barr & 
Figure I6. Structure and domains of the Aurora kinases family. Members of Aurora family are 
composed by three domains: regulatory, catalytic and destruction box. Key residues are represented 
(Goldenson & Crispino, 2015). 
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Gergely, 2007; Petretti et al, 2006). During late S/early G2 Aurora A exchanges continuously between the 
centrosomes and a cytoplasmatic pool (Berdnik & Knoblich, 2002). However, there is an Aurora A 
expression and activity peak in late G2 and the protein is concentrated at centrosomes (Carmena & 
Earnshaw, 2003; Lukasiewicz & Lingle, 2009). Although Aurora A localization in centrosomes and in the 
mitotic spindle during mitosis is universally accepted, its location in interphase is not clear. Some of the 
observed localizations are in the centrosome or, in Xenopus egg extract, along the MTs (Lukasiewicz & 
Lingle, 2009; Sardon et al, 2008).  
Aurora A has several functions related to cell division.  It promotes mitotic entry by phosphorylating 
CDC25B, which in turns activates Cyclin B/Cdk-1 complex at the centrosomes (Cazales et al, 2005; 
Dutertre & Prigent, 2003). Moreover, Aurora A phosphorylates and activates Plk-1 which regulates many 
others proteins involved in cell cycle progression (Lee et al, 2013; Seki et al, 2008) (Fig. I7).  
 
 
 
 
 
 
 
 Aurora A is also involved in centrosome separation after duplication at the early mitosis. Although 
Aurora A seems not be implicated during centrosome duplication, its absence impedes their separation, 
resulting in a monopolar spindle (Barr & Gergely, 2007). However, in some cases there is a bipolar spindle 
that are disorganized when Aurora A function is blocked (Peset et al, 2005). It is consistent with that there 
are two distinct pathways for centrosome separation: a nuclear-envelope-dependent pathway and a nuclear-
envelope-independent one (Barr & Gergely, 2007). In late G2 phase, during centrosome maturation, the 
pericentrosomal matrix (PCM) directs the MT nucleation through the recruitment of MT nucleating factors 
such as the gamma-tubulin ring complex (γ-TURC) (Hannak et al, 2001). This recruitment allows the 
incorporation of αβ-tubulin dimers into new formed MTs (Wiese & Zheng, 2006). It has been established 
an evolutionary conserved role for Aurora A in centrosome maturation (Hannak et al, 2001; Mori et al, 
2007; Sardon et al, 2008) and although the effect caused by Aurora A depletion in different species is not 
exactly the same, some similarities exist. In this sense, Aurora A depletion in Caenorhabditis elegans 
disrupts the accumulation of γ–tubulin, resulting in a decrease of centrosomal MT levels (Hannak et al, 
2001). Furthermore, after nuclear envelope breakdown, centrosome activity increases through the action of 
the Ran-GTP gradient that emanates from the condensed chromosomes (Gruss et al, 2001). It has been 
Figure I7. Regulation of mitotic entry 
by Aurora A. During G2/M transition, 
Aurora A activates Plk-1 which in turns is 
going to direct the phosphorylation of 
several substrates involved in cell cycle 
progression (Modified from Lee et al, 
2013). 
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described that Aurora A activity enhances the Ran-GTP dependent pathway both at the centrosome and in 
the cytoplasm through the phosphorylation of factors that participate in this pathway (Sardon et al, 2008). 
This process may be mediated by some proteins that are substrates of Aurora A and targets of Ran-GTP 
such as TPX2 or Maskin (Gruss et al, 2001; Gruss & Vernos, 2004).   
Moreover, Aurora A is also linked to mitotic MT dynamics and stability through the transforming 
acidic-coiled-coil-containing (TACC) family proteins. TACC proteins interact with the ch-TOG/XMAP215 
family of centrosomal proteins which are involved in stabilization of MTs and control their plus-end 
dynamics (Barr & Gergely, 2007) (Fig. I8).  
 
 
 
 
 
 
 
 
 
 
  
 
Figure I8. Control of MT stability by 
Aurora A. TACC is phosphorylated by 
Aurora A directly or through Ndel1 in the 
centrosomes. TACC binds to MTs when they 
are complexed with the MT-stabilising 
protein ch-TOG/XMAP215. This interaction 
protects the MTs from the MKAC-induced 
destabilization (Modified from Barr & 
Gergely, 2007). 
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2. Objectives 
 
Based on the role of Aurora A in controlling MT dynamics, we postulate that Aurora A may allow the 
maturation of the centrosome in the stimulated T lymphocytes during the IS, promoting the proper 
activation of T cells.  
In order to challenge our hypothesis, our main aims were: 
 
1) Assess the specific location of Aurora A in T cells during the IS 
 
2) Study the role of Aurora A in cytoskeletal dynamic and in vesicular traffic 
 
3) Analyse the effect of Aurora A inhibition in TCR signalling pathway 
 
4) Control of Lck activity by Aurora A 
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3. Materials and methods 
 
3.1 Reagents and antibodies 
 
- Human Fibronectin (FN) and Poly-L-Lys (PLL) from Sigma. 
- Enterotoxins E (SEE; 0.3 µg/mL) and B (SEB; 5 µg/mL) from Staphylococcus aureus were from Toxin 
Technology.  
- HA (Hemagglutinin) peptide (200 µg/mL) from Lifetein LLC. 
- Recombinant human Lck, histidine tagged from MBL. 
- DMSO (Dimethyl Sulfoxide) fron Sigma-Aldrich. 
- Cell Tracker Blue CMAC (7-amino-4-chloromethylcoumarin; 0.1µM) from Molecular Probes-
Invitrogen. Blue excitation/emission spectra (353/466 nm maxima) is a fluorescent dye well suited for 
monitoring cell movement or location. This dye is well retained, allowing for multigenerational 
tracking of cellular movements. The blue excitation/emission spectra are ideal for multiplexing with 
green and red fluorescent dyes and proteins. Cells were incubated with CMAC in serum free RPMI 
1640 + GlutaMAXTM – I + 25mM HEPES for 30 min at 37º C. Non-internalised dye was removed 
by washing twice with PBS and once with RPMI 1640 + GlutaMAXTM – I + 25mM HEPES with 
serum. 
- Phalloidin conjugated to Alexa Fluor 647 (1:100) from Thermofisher Scientific. Phalloidin is a toxin 
which binds and stabilizes F-actin.  
- Prolong Gold anti-fade mounting medium from Molecular Probes-Invitrogen. 
- Aurora A inhibitor (MLN8237; 10 µg/ml) and Aurora B inhibitor (AZD1152; 100 nm/ml) from 
Selleckchem.  
- Anti-human CD3; clon HIT3a (5 µg/ml; eBioscience) and anti-human CD28; clon CD28.2 (2µg/ml; 
BD Pharmingen) 
- Anti-mouse CD3ε; clon 2C11 (10 µg/ml; BD Pharmingen) and anti-mouse CD28; clon 37.51 (5 µg/ml; 
BD Pharmingen) 
- Murine IL-7 (5 ng/ml; PreproTech) 
- Human IL-2 (50 U/ml) from National Institutes of Health AIDS Research and Reference Reagent 
Program. 
- Goat anti-Armenian hamster IgG (10 µg/ml) from Jackson ImmunoResearch 
- Antibodies used are in the table below: 
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Primary 
Antibody Host species Specificity Manufacturer Use 
OKT3 Mouse CD3ε Biolegend IF 
Anti-P-LAT Rabbit LAT Y132 Abcam WB 
Anti-LAT Rabbit LAT Santa Cruz WB 
Anti-Tubulin DM1A Mouse Tubulin Sigma WB 
Anti-Tubulin-FITC Mouse Tubulin Sigma IF 
Anti-β-Actin Mouse β-Actin Sigma IF, WB 
Anti-P-ERK 1/2 Rabbit ERK 1/2 T202/204 Calbiochem WB 
Anti-ERK 1/2 Mouse ERK Invitrogen WB 
Anti-P-Src Rabbit Lck Y394 Invitrogen WB 
Anti-Lck Rabbit Lck Cell Signaling IF, WB 
Anti-Lck Rabbit Lck Millipore IP 
Anti-P-PKCθ Rabbit PKCθ T538 Cell Signaling WB 
Anti-PKCθ Mouse PKCθ Cell Signaling WB 
Anti-PKCθ Sc-13/18 Goat PKCθ Santa Cruz IF 
Anti-P-CD3ζ Rabbit CD3ζ Y83 Abcam WB 
448 Mouse CD3ζ Dr. B. Alarcón WB 
Anti-P-PLCγ1 Rabbit PLCγ1 Y783 Cell Signaling WB 
Anti-PLCγ1 Rabbit PLCγ1 Cell Signaling WB 
Anti-P-Aurora A Mouse Aurora A T288 Abcam IF 
Anti-Aurora A Rabbit Aurora A Abcam WB 
Anti-V5 Mouse V5 tag Invitrogen IP, WB 
Anti-Rac1 Mouse Rac1 BD Pharmingen Pull-down, WB 
Anti-GST Mouse GST Dr. B. Alarcón Pull-down, WB 
Secondary 
Antibody Host species Specificity Manufacturer Use 
GAM-488/568/647 Goat IgG de ratón Invitrogen IF 
GAR-488/568/647 Goat IgG de conejo Invitrogen IF 
DAM-488/568/647 Donkey IgG de ratón Invitrogen IF 
DAR-488/568/647 Donkey IgG de conejo Invitrogen IF 
DAG-488/568/647 Donkey IgG de cabra Invitrogen IF 
GAM-HRP Goat IgG de ratón Pierce WB 
GAR-HRP Goat IgG de conejo Pierce WB 
DAG-HRP Donkey IgG de cabra Pierce WB 
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3.2 Cells 
 
- The human Jurkat-derived T-cell line J77 (Vαl.2 Vβ8+ TCR) and the lymphoblastoid B-cell lines Raji 
(Burkitt lymphoma) and Hom2 (HLA-DR1 EBV-transformed) were cultured in RPMI 1640 + 
GlutaMAX–I + 25 mM HEPES (Gibco-Invitrogen) supplemented with 10% fetal bovine serum 
(Hyclone, Thermofisher). The human Jurkat-derived CH7C17 cells (Vβ3+ transgenic TCR, specific 
for HA peptide) were grown in the same medium supplemented with 400 μg/ml hygromycin B (Roche 
Diagnostics) and 4 μg/ml puromycin (Invitrogen).  
 
- CH7C17 clones expressing EB1-GFP were generated by CH7C17 transfection and post-selection with 
G418 (1 mg/ml).  
 
- HEK293T cells were cultured in DMEM medium (Invitrogen) supplemented with 10% fetal bovine 
serum, 50 IU/ml penicillin and 50 μg/ml streptomycin.  
 
- Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats obtained from 
healthy donors by separation on a Biocoll gradient (Biochrom) according to standard procedures. 
Monocytes were separated from PBMCs by a 30 minute adherence step at 37 °C in RPMI 
supplemented with 10% fetal calf serum. Non-adherent cells were washed off and CD4+ T cells were 
purified from PBMCs using MACS (magnetic-activated cell sorting; Miltenyi Biotech). Non-adherent 
cells were obtained after 30 min of the adhesion step at 37 °C. In order to generate SEE-responsive 
human T lymphoblasts, PBMCs were cultured five days in the presence of SEE (0.1 μg/ml) and then, 
phytohemagglutinin (5 μg/ml) was added for 2 days. To favor its proliferation, IL-2 (50 U/mL) was 
added later to the medium every 2 days for a time period of 8 days. These studies were performed 
according to the principles of the Declaration of Helsinki and approved by the local Ethics Committee 
for Basic Research at the Hospital La Princesa (Madrid); informed consent was obtained from all 
human volunteers. These studies were performed according to the principles of the Declaration of 
Helsinki and approved by the local Ethics Committee for Basic Research at the Hospital La Princesa 
(Madrid); informed consent was obtained from all human volunteers. 
 
3.3 Mice  
 
The Aurora A conditional model has been described (Perez de Castro et al, 2013). These mice carry 
an Aurka(lox) conditional allele and the RERTert allele expressing an inducible Cre recombinase. After the 
appropriate crosses, we obtained the experimental Aurka(lox/lox); RERT(ert/ert) and control Aurka(+/+); 
RERT(ert/ert) mice used in this study. Cre activation upon tamoxifen treatment induces conversion of the 
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Aurka(lox) allele to the Aurka(Δ) allele. The Aurora kinase A (AurkA)-inducible mouse model has been 
reported recently (Piazzolla et al, 2014). This model was generated using the tetracycline-inducible single-
copy transgenic system (Beard et al, 2006), and carries the M2-rtTA gene inserted within the Rosa26 allele 
and a cassette containing the Aurora A cDNA under the control of the doxycycine-responsive promoter 
(tetO) inserted downstream of the Col1a1 locus. The final mouse model, Col1a1tetO-Aurka/+; 
Rosa26rtTA/rtTA, overexpresses exogenous Aurora A upon doxycycline treatment in a wide range of 
proliferative and non-proliferative tissues and cells. 
Both Aurora A mouse models were maintained in a mixed background (129/Sv, CD1, C57BL/6J, and 
FVB/N). Mice were housed in the pathogen-free animal facility of the Centro Nacional de Investigaciones 
Oncológicas (Madrid) in accordance with the animal care standards of the institution. These animals were 
observed on a daily basis, and sick mice were killed humanely in accordance with the Guidelines for 
Humane Endpoints for Animals used in biomedical research. All animal protocols were approved by the 
Instituto de Salud Carlos III Committee for Animal Care and Research.  
Mouse CD4+ T cells were obtained from single-cell suspensions of the spleen and mesenteric lymph 
node (MS-LN). The cell suspensions were incubated with biotinylated antibodies against CD8, CD16, 
CD19, CD24, CD117, major histocompatibility complex (MHC) class II (I-Ab), CD11b, CD11c and DX5, 
and were subsequently incubated with streptavidin microbeads (MACS; Miltenyi Biotec). CD4+ T cells 
were negatively selected in an auto-MACS Pro Separator (Miltenyi Biotec). Cells were then labeled with 
antibodies to CD4 and CD25 and analyzed by flow cytometry to confirm their purity and resting status. For 
conditional knockout and knockin studies, mouse CD4+ T cells were cultured with tamoxifen for 96 h 
(Aurora A gene deletion model) or doxycycline for 20 h (Aurora A overexpression model) in RPMI 1640 
+ GlutaMAX–I + 25 mM HEPES (Gibco-Invitrogen) supplemented with 10% fetal bovine serum (Hyclone, 
Thermofisher), 50 IU/ml penicillin, 50 μg/ml streptomycin, and 5ng/mL murine IL-7.  
 
3.4 Plasmids, siRNAs and transfection  
 
The plasmid encoding GFP-EB3 was generously provided by Dr. A. Akhmanova (Utrecht University; 
Utrecht, The Netherlands) (Grigoriev & Akhmanova, 2010) and the plasmid encoding Aurora A-GFP was 
reported previously (Perez de Castro et al, 2011). T cell lines were transfected with specific double-stranded 
siRNA against human Aurora Kinase A 3’UTR (CCCUCAAUCUAGAACGCUA) (Plotnikova et al, 2012) 
or a scramble negative control (CUAGGGUGCCGAGUGUGUU). For transfection, T cell lines were 
centrifuged at 1200 rpm for 5min and washed with HBSS (Hank’s balance salt solution; Lonza) and 
resuspended in Opti-Mem I (GIBCO-Invitrogen) (15x106 cells in 400 μl). Plasmid encoding GFP-EB3 (5 
μg) or Aurora A-GFP (5 µg) was added to cells, and transfection was performed with the gene-pulser III 
system from Bio-Rad Laboratories (240 V, 975 m, aprox 27 ms). After electroporation, cells were cultured 
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in 9 ml RPMI 1640 + GlutaMAXTM–I + 25mM HEPES medium. After 4 h, 500 μL of fetal bovine serum 
was added to the cell medium. Experiments were performed 24 h after transfection. The plasmids encoding 
Aurora A-V5 wild type (WT) or kinase dead mutant (KD) (24µg) were transfected with lipofectamin 
(Invitrogen) in HEK293T cells. Experiments were performed 24 h after transfection.  
3.5 T cell activation  
3.5.1 Human TCR stimulation 
T cells were incubated for the indicated times with latex microbeads (6.4 µm diameter) conjugated 
to anti-CD3 antibody (10 μg/ml) and anti-CD28 antibody (5μg/ml).  
3.5.2 Mouse TCR stimulation  
T cells were incubated with anti-CD3 antibody (10 μg/ml) and anti-CD28 antibody (5μg/ml) for 15 
(4ºC) followed by incubation with goat anti-Armenian hamster IgG for 15 minutes (4ºC).  
3.5.3 Antigen stimulation 
Raji cells were pulsed with 0.3 μg/ml SEE (30 min) and mixed with J77 cells (1:5); alternatively, 
Hom2 cells pulsed with 200 μg/ml HA peptide (2 h) or with 5 μg/ml SEB (30 min) and were mixed 
with CH7C17 cells (1:5) in HBSS. Where indicated, cells were pretreated with MLN8237 (10 μM) 
or AZD1152 (100 nM) or vehicle for 45 min at 37 ºC in HBSS prior to stimulation with the 
corresponding APC or anti-CD3 and anti-CD28 antibodies. Cells were centrifuged at low speed for 
the indicated times at 37ºC to favor the formation of conjugates.  
 
3.6 Cell lysis and immunoblotting 
 
Cells were lysed in 50 mM Tris–HCl pH 7.5 containing 1% NP40, 0.2% Triton X-100, 150 mM NaCl, 
2 mM EDTA, 1.5 mM MgCl2, and phosphatase and protease inhibitors. Lysates were spin at 14000 rpm (4 
°C, 10 min) to remove debris and nuclei. Proteins were resolved by SDS–PAGE and transferred to 
nitrocellulose membranes. After blocking with TBS (Tris-buffered saline) containing 0.2% TWEEN and 
5% BSA, membranes were blotted with primary antibodies (o/n at 4 ºC) and peroxidase-labeled secondary 
antibodies (30 min) and detected with the ImageQuant LAS-4000 chemiluminiscence&fluorescence 
imaging system (Fujifilm). 
 
3.7 Cell conjugate formation, immunofluorescence and IS analysis.  
 
Raji B cells or Hom2 B cells were washed once with HBSS and loaded with the CMAC cell tracker 
(10 μM) and with SEE or SEB for 30 min or HA peptide for 2 h at 37 ºC. T cells (1 × 105 cells) were mixed 
with the corresponding APC (1:1) and plated onto Poly-L-Lys-coated slides (50 μg/ml; 1h at 37ºC). Cells 
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were allowed to settle for 20 min at 37 °C, fixed with 4% paraformaldehyde and 0.12mM sucrose in PHEM 
(60 mM PIPES, 25 mM Hepes, 5 mM EGTA, 2 mM MgCl2), and permeabilized for 5 min at room 
temperature with 0.2% Triton X-100 in immunofluorescence solution (PHEM containing 3% BSA, 100 
μg/ml γ-globulin and 0.2% azide). Cells were blocked for 30 min with immunofluorescence solution and 
stained with the indicated primary antibodies (5 μg/ml) followed by Alexa Fluor 488, 568 or 647-labeled 
secondary antibodies, alexa-conjugated phalloidin (5 μg/ml) or FITC-conjugated anti--tubulin (0.1 
µg/ml). Cells were mounted on Prolong Gold and analyzed with a Leica SP5 confocal microscope (Leica) 
fitted with a HCX PL APO 63x/1.40-0.6 oil objective, and images were processed and assembled using 
Image J software (http://rsbweb.nih.gov/ij/) and Photoshop software. For quantification in individual ISs, 
we used a home-made plugin for Image J software (http://rsbweb.nih.gov/ij/) called ‘Synapse Measures'. 
By comparing fluorescence signals from multiple regions of the T cell, APC, IS, and background 
fluorescence, the program yields accurate measurements of localized immunofluorescence. A detailed 
description of Synapse Measures, including the algorithms used, is described (Calabia-Linares et al, 2011). 
 
3.8 Immunoprecipitation, mass spectrometry and analysis of phosphorylation 
 
For Lck immunoprecipitation assay, human lymphoblast pretreated with MLN8237 (10 µM) or vehicle 
(DMSO) for 30 min, were activated with Raji preloaded with SEE for 2 min at 37 ºC.  Then, cells were 
lysed for  40 min at 4ºC in extraction buffer  with 50 mM Tris–HCl pH 7.5 containing 0.5% NP40, 150 mM 
NaCl, 2 mM EDTA, 1.5 mM MgCl2, and phosphatase and protease inhibitors. Lysates were spun at 14000 
rpm (4°C, 10 min) to remove debris and nuclei.  The anti-Lck antibody was allowed to bind with Protein 
G-conjugated sepharose beads (GE Healthcare) overnight at 4ºC and then mixed with the extracts. The 
mixture was left in stirring at 4ºC for 2 hours and then beads were washed ten times with the same buffer 
used for lysis without detergents. As a control, we used beads preincubated with the extracts. For Aurora A 
immunoprecipitation, Aurora A-V5 WT or KD transfected HEK293T cells were lysed with RIPA buffer 
with 1% Triton X-100, 0.5% deoxycholate (Sigma Aldrich), 0.1% SDS in Tris buffer saline and sonicated 
(3x30 s pulses). The anti-V5 antibody was mixed with the extracts, and left in stirring at 4 ºC for 2 h and 
then Protein G-conjugated sepharose (GE Healthcare) was added for 1 h in stirring at 4 ºC. Bead were 
washed three times with the buffer kinase with 20mM Hepes pH 7.4 containing 150mM KCl, 10mM MgCl2, 
1mM EGTA, 0.5mM DTT and phosphatase and protease inhibitors and once with buffer kinase plus NaCl 
0.5mM. Beads were incubated with 0.5µg of recombinant Lck in buffer kinase plus 10mM ATP during 30 
min at 30 ºC. For proteomic analysis, the samples were trypsin-digested using the whole proteome in-gel 
digestion protocol (Bonzon-Kulichenko et al, 2011). The peptides produced by digestion were vacuum-
dried and redissolved in 1% trifluoroacetic acid for desalting in reversed-phase C-18 extraction cartridges 
(Oasis, Waters Corporation, Milford, MA, USA). High-resolution parallel reaction monitoring of 
phosphorylated peptides was carried out on an Easy nLC 1000 nano-HPLC apparatus (Thermo Scientific, 
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San Jose, CA, USA) coupled to a hybrid linear ion trap-orbitrap (Orbitrap Elite, Thermo Scientific). 
Peptides were suspended in 0.1% formic acid and then loaded onto a C-18 reversed-phase nano-column (75 
μm I.D., 50 cm) and separated in a continuous gradient consisting of 8-30% B for 15 min and 30-90% B 
for 2 min (B = 90% acetonitrile, 0.1% formic acid) at 200 nl/min. Peptides were ionized using a Picotip 
emitter nanospray needle (New Objective, Woburn, MA, USA). Each MS run consisted of enhanced FT-
resolution spectra (30,000 resolution) in the 390–1600 m/z range followed by data-independent MS/MS 
spectra of 11 parent ions acquired along the chromatographic run. The AGC target value in the Orbitrap for 
the survey scan was set to 1,000,000. Fragmentation in the linear ion trap was performed at 35% normalized 
collision energy with a target value of 10,000 ions, and the dynamic exclusion was set to 0.5 min. Data 
analysis was performed with Xcalibur 2.2 (Thermo Scientific). 
 
3.9 Time-lapse confocal and total internal reflection fluorescence (TIRF) video microscopy.  
 
Raji APCs (5x105; SEE-pulsed or unpulsed) were allowed to adhere to fibronectin-coated coverslips 
in Attofluor open chambers (Molecular Probes-Invitrogen) at 37 ºC in a 5% CO2 atmosphere. The cells 
were maintained in 1 ml HBSS (1% fetal bovine serum, 25 mM HEPES). T cells were added (1:1 ratio) and 
a series of fluorescence and differential interference contrast frames were captured using a TCS SP5 
confocal laser scanning unit attached to an inverted epifluorescence microscope (DMI6000) fitted with an 
HCX PL APO 63x/1.40-0.6 oil objective. Images were acquired and processed with the accompanying 
confocal software (LCS; Leica) and Image J software (http://rsbweb.nih.gov/ij/). For TIRF microscopy 
(TIRFm), T cells stably expressing EB3-GFP or transfected with EB3-GFP and CD3ξ-mCherry were 
allowed to settle onto glass bottom dishes (No 1.5 Mattek; Ashland, MA, US) coated with anti-CD3 (10 
µg/ml) and anti-CD28 (3 µg/ml). Recording was initiated 3 minutes after cells were plated, and cells were 
visualized with a Leica AM TIRF MC M system mounted on a Leica DMI 6000B microscope coupled to 
an Andor-DU8285_VP-4094 camera fitted with a HCX PL APO 100.0x1.46 OIL objective. For 
mCherryActin expressing T cells, recording was initiated upon addition of cells to the glass bottom dishes. 
Images were processed with the accompanying confocal software (LCS; Leica). The laser penetrance used 
was 150 or 200 nm for both laser channels (488 and 561 nm), using the same objective angle. Time-lapse 
settings were optimized for each type of experiment and are specified throughout the text. Synchronization 
was performed with the accompanying Leica software, and images were processed with Leica software, 
matlab and Image J software (http://rsbweb.nih.gov/ij/). 
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3.10   Quantitative real-time PCR 
 
RT–PCR was performed with 1 μg of RNA isolated with Trizol RNA reagent (Invitrogen, Eugene, 
OR, USA) from CD4+ T cells obtained from healthy donors. mRNA levels of IL-2, CD25 and CD69 were 
determined in triplicate using the Power SYBR Green PCR master mix from Applied Biosystems 
(Warrington, UK). Expression levels were normalized to the expression of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Primer sequences are listed in table below. 
Oligos 5´- 3´ Forward Sequence 5´- 3´ Reverse Sequence 
GAPDH AGCCACATCGCTCAGACAC 
 
GCCCAATACGACCAAATCC 
 
IL-2 AAGTTTTACATGCCCAAGAAGG 
 
AAGTGAAAGTTTTTGCTTTGAGCTA 
 
CD69 CAAGTTCCTGTCCTGTGTGC 
 
GAGAATGTGTATTGGCCTGGA 
 
CD25 CAGCCCCAGCTCATATGCA 
 
TGAGGCTTCTCTTCACCTGGAA 
 
  
 
 
 
 
 
 
 
 
Results 
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4. Results 
 
4.1 Localization of Aurora A at the IS 
 
To assess the specific location of activated Aurora A, we conjugated human CD4+ T cells from 
peripheral blood from healthy donors with beads coated with stimulatory anti-CD3 and anti-CD28 
antibodies, and stained with anti-phospho-specific antibody against the Aurora-T288 residue, that 
detects active Aurora A. In these experiments, T288-phosphorylated endogenous Aurora A was found 
in two different pools, one in the centrosome and the other at the T cell-bead contact region (examples 
of conjugates at different stages of the process are shown, Fig.  R1a); the low signal of activated Aurora 
A in non-stimulated control conjugates was not detected at the IS (Fig.  R1a). Pretreatment of 
peripheral-blood-derived human CD4+ T cells with the specific Aurora A inhibitor MLN8237 blocked 
the phosphorylation of Aurora A (Fig.  R1a). Quantitative analyses showed that phosphorylated Aurora 
A is accumulated at the IS in stimulated CD4+ T cells, and that this is prevented by MLN8237 treatment 
(Fig.  R1b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R1. Aurora A is located at the IS contact area and is activated upon TCR triggering. 
(a) Maximum Z projection of a confocal stack of human primary CD4+ T cells pretreated with 
vehicle (DMSO) or Aurora A inhibitor (MLN8237, 10 µM) and conjugated with anti CD3/CD28-
coated beads. Images show three representative conjugates in DMSO and two in MLN8237-
treated cells at different stages of cell conjugation. Cells were fixed and stained for PKCθ (red), 
T288-phosphorylated Aurora A (magenta) and α-tubulin-FITC (green). Bright field with DAPI 
frames are included. Bar, 10 µm. (b) Quantification of T288-phosphorylated Aurora A 
accumulation at the IS contact area in conjugates as in a from three independent experiments 
(n=93 in non activated, n=105 in DMSO, n=109 in MLN8237). Data represent means ± SD. 
Means were compared with a t-test. (**** p < 0.0001). 
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In order to confirm the specificity of the T288-Aurora A antibody, we transfected J77 T cells with 
specific siRNAs for Aurora A for silencing it. Staining of phosphorylated endogenous Aurora A upon 
TCR stimulation was abolished, confirming the specific binding of the antibody (Fig.  R2).  
 
 
 
Active Aurora A also localized at the IS in conjugates of naïve mouse OTII T lymphocytes with 
primary dendritic cells pulsed or not (control) with OVA peptide (Fig. R3). These results clearly show 
that TCR triggering promotes the activation of Aurora A and its recruitment to the IS.  
   
Figure R3. Active Aurora A is located at the IS in 
mouse CD4+ T cells.  Maximum Z projections of 
confocal stacks of transgenic OTII CD4+ cells 
conjugated with OVA peptide-pulsed bone-marrow-
derived dendritic cells (DC). Cells were incubated 
for 30 min, fixed and immunostained for T288-
phosphorylated Aurora A (magenta) and actin 
(green). The right-hand image shows CMAC cell 
tracker labeling of DCs (cyan) and bright field. Bar, 
10 µm. 
Figure R2. Specific silencing of Aurora A.  Maximum Z stack projection of a confocal XYZ-
stack of Jurkat T cells transfected with a specific siRNA against Aurora A (siAUA) or a scrambled 
negative control (siControl) and conjugated with SEE-pulsed Raji B cells. Cells were incubated 
for 30 min, fixed and stained for α-tubulin (green), T288-phosphorylated Aurora A (magenta) 
and actin (red). A merged fluorescence image is shown. The right-hand image shows Raji cells 
labeled with CMAC cell tracker (cyan) and bright field. Bar, 10 µm. 
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To parse the localization of activated Aurora A with respect to total Aurora A, we transfected 
primary CD4+ T cells with Aurora A-GFP WT or Aurora A-GFP KD (kinase dead mutant) and then 
conjugated the transfected cells with stimulatory anti-CD3/CD28-coated beads (Fig.  R4a). 
Quantitative analysis of Aurora A-GFP or active Aurora A (Aurora A T288) accumulation 
demonstrated that it is mainly found at the IS (Fig. R4b). However, Aurora A KD accumulation at the 
IS is significantly decreased, compared to WT (Fig. R4b). Moreover, overexpression of the Aurora A-
GFP KD mutant, dispersed the remaining active protein (Fig. R4b). Thus, the phosphorylated active 
form of Aurora A is specifically recruited to the IS.   
 
4.2 Aurora A in MT dynamics and in MTOC translocation 
 
Aurora A plays an important role in the dynamics of the centrosome during mitosis (Berdnik & 
Knoblich, 2002; Hannak et al, 2001). To ascertain its possible function in microtubule dynamics and 
centrosomal polarity during T cell activation, we analyzed the dynamics of the microtubular network 
in CH7C17 T cells transiently transfected or stably expressing an EB3-GFP fusion protein (EB3 cells; 
Fig.  5a and Supplementary Movie 1). EB3 and EB1 (End-Binding proteins) are plus-tip-tracking 
proteins that are also found in the pericentrosomal matrix and promote MT growth (Etienne-
Manneville, 2010). Cells were settled on anti-CD3/CD28-coated chambers and time-lapse confocal 3D 
Figure R4. Both Aurora A-GFP and active Aurora A localize at the IS. (a) Maximum Z 
projection of a confocal stack of human primary CD4+ T cells transfected with Aurora A-GFP 
WT or Aurora A-GFP KD (green) and conjugated with anti CD3/CD28-coated beads. Cells were 
incubated for 30 min, fixed and stained for T288-phosphorylated Aurora A (magenta). Bright 
field with DAPI frames are included. Bar, 10 µm. (b) Quantification of T288-phosphorylated 
Aurora A and transfected Aurora A accumulation at the IS contact area in conjugates as in a from 
three independent experiments (n=45 in Aurora A-GFP WT, n=29 in Aurora A-GFP KD). Data 
represent means ± SD. Means were compared with a t-test. n.s., non-significant. (* p < 0.05), (** 
p < 0.01), (*** p < 0.001). 
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imaging was performed by XYZ-stack acquisition. The stimulating surface allows IS-like formation, 
associated centrosome polarization and MT polymerization (Martin-Cofreces et al, 2012). EB3 cells 
were pre-treated or not (vehicle) with MLN8237 for 30 min before imaging. Maximal projection of 
the XYZ-stack (Fig.  R5a and Supplementary Movie 1) revealed that the relative amount of EB3-GFP 
incorporated into microtubule plus-ends (TIPs) was clearly decreased in Aurora A-inhibited cells. This 
effect was measured in 3D as the ratio of EB3-GFP fluorescence incorporated in TIPs with respect to 
the whole cell fluorescence using Imaris software, confirming that Aurora A-inhibited cells polymerize 
microtubules less efficiently (Fig.  R5b and Supplementary Movie 1). The amount of polymerized MT 
observed along the time-course was clearly decreased in MLN8237-treated cells (Fig.  R5a).  
 
To further assess the function of Aurora A in primary naïve T cells, we used a mouse model of 
conditional Aurora deficiency. CD4+ cells were isolated from lymph nodes and spleens of experimental 
[Aurka(lox/lox); RERT(ert/ert)] (KO mice) and control [Aurka(+/+); RERT(ert/ert)] (WT mice), 
treated with tamoxifen and IL-7 for 96 h to suppress Aurora A expression (Fig R6a). These cells were 
transfected with a plasmid encoding EB3-GFP, and then activated with anti-CD3/CD28 stimulating 
monoclonal antibodies (Fig.  R6b and c and Supplementary Movie 2). We found that Aurora A-
deficient T cells had significantly less EB3 incorporation in microtubule +TIPs than their WT 
counterparts (Fig. R6b and c and Supplementary Supplementary Movie 2). Furthermore, the effect of 
Aurora A deficiency was similar to the effect of the MLN8237 inhibitor on WT cells, while the 
inhibitor did not have additional effects on Aurora A KO cells, suggesting that these and previously 
recorded effects of the inhibitor were Aurora A-specific.  
Figure R5. Microtubule dynamics at the IS is impaired by Aurora A chemical inhibition. 
(a) Imaging of EB3-GFP-expressing CH7C17 T cells, pretreated with DMSO or MLN8237 and 
settled on corresponding anti-CD3/CD28-coated glass-bottom chambers. Maximal projection of 
XYZ-stacks for fluorescence and single bright field (BF) images are shown. Bars, 10. (b) Ratio 
of EB3-GFP fluorescence incorporated in TIPs from XYZ-stack from three independent 
experiments (0s; n=34 in DMSO, n=43 in MLN8237). Data represent means ± SD. Means were 
compared with a Mann-Whitney test. (**** p < 0.0001). 
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We next tracked the dynamics of microtubule growth using EB3-GFP imaging and TIRF 
microscopy in cells settled on anti-CD3/CD28-coated surfaces to improve the XY spatial and time 
resolution (Dixit & Ross, 2010; Grigoriev & Akhmanova, 2010; Manneville, 2006). EB3 cells were 
treated with MLN8237 or DMSO (vehicle) for 30 min before imaging, and images were taken every 
300 ms. MLN8237-treated EB3-GFP cells had fewer EB3-decorated tips emerging from the 
centrosome, indicating impaired microtubule growth (Fig.  R7a and b and Supplementary Movies 3 
and 4). MT growth was similarly impaired in Aurora-KO primary CD4+ T cells, displaying fewer and 
slower growing microtubules than control cells (0.140 +/-0.037 µm.s-1 and 0.190 +/-0.023 µm.s-1, 
respectively; mean +/- SD) (Fig.  R7c and d and Supplementary Movies 5 and 6). These results thus 
show that the microtubule network at the immune synapse is disrupted in T cells with defective Aurora 
A activation.  
 
 
 
 
 
Figure R6. Aurora A gene ablation impairs EB3 incorporation in MT +TIPs. (a) Immunoblot 
analysis of Aurora A protein expression in CD4+ T cells WT and KO. (b) Imaging of EB3-GFP-
expressing Aurora A-deficient and control CD4+ T cells, pretreated with DMSO or MLN8237 
and settled on corresponding anti-CD3/CD28-coated glass-bottom chambers. Maximal projection 
of XYZ-stacks for fluorescence and single bright field (BF) images are shown. Bars, 10 or 5 µm, 
respectively. (c) Ratio of EB3-GFP fluorescence incorporated in TIPs from XYZ-stack from three 
independent experiments (0s; n=25 in WT, n=17 in KO, n=22 in WT MLN8237 and n=17 in KO 
MLN823). Data represent means ± SD. Means were compared with a Mann-Whitney test. n.s., 
non-significant. (* p < 0.05), (** p < 0.01). 
 
 48 
RESULTS 
 
To assess the localization of the MTOC and the EB3-GFP fluorescence by 3D and orthogonal 
projections of the XYZ-stacks in EB3 cells. Cells were settled on anti-CD3/CD28-coated surfaces 
during 3 min and maximal fluorescence, corresponding to MTOC was analyzed (Fig. R8a and b). 
MTOC is detected close to the stimulating surface (Fig.  R8a) and there is not significant changes in 
the translocation in MLN8237 treated cells (Fig. R8b). This can be also observed by comparing bottom 
and top slices of the XYZ-stacks (Fig.  R8c). Moreover, no significant change on MTOC translocation 
in Jurkat T cells pre-treated or not with MLN8237 and conjugated with Raji B cells was observed 
either at 10 or 30 min of activation (Fig.  R8d). 
 
          
Figure R7. Aurora A gene ablation impairs MT dynamics at the IS. (a) Map of the trajectories 
of EB3-GFP decorated microtubule plus tips in human CH7C17 T cells pretreated with DMSO 
or MLN8237 and settled on anti-CD3/CD28-coated glass-bottom chambers. Images were taken 
every 300 ms under a TIRF microscope at a penetrance of 150 nm. MT tips were tracked with 
Imaris software over 5 min. Maximal projections of the time-lapse from representative cells are 
shown. Bar, 10 µm. (b) Quantification of the number of microtubule plus tip tracks presented in 
a from three independent experiments (n=7 in DMSO, n=9 in MLN8237). (c) Map of the 
trajectories of EB3-GFP decorated microtubule plus tips in Aurora A-deficient and control WT 
CD4+ T cells and settled on anti-CD3/CD28-coated glass-bottom chambers. Images were taken 
every 300 ms under a TIRF microscope at a penetrance of 150 nm. MT tips were tracked with 
Imaris software over 2 min. (d) Quantification of the number of microtubule plus tip tracks 
presented in c from three independent experiments (n=6). Error bars represent interquartile rage. 
Medians were compared with a Mann-Whitney test. n.s., non-significant. (* p < 0.05), (** p < 
0.01). 
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We also analyzed the localization of the MTOC and the EB3-GFP fluorescence by 3D and 
orthogonal projections of the XYZ-stacks in mouse CD4+ T cells. Cells from WT and Aurora A KO 
mice were transfected with the plasmid encoding EB3-GFP and then settled on anti-CD3/CD28-coated 
surfaces during 3 min. MTOC and EB3-GFP tracking of MTs was also observed at the bottom of the 
Figure R8. Aurora A inhibition does not affect MTOC translocation to the IS. (a) Orthogonal 
and 3D projections from XYZ-stacks. Dotted white or red lines indicate contact with substrate or 
media, respectively. (b) Ratio of the MTOC location from the IS-like from three independent 
experiments (n=38 in DMSO, n=44 in MLN8237). (c) Single slices from the XYZ-stack of 4D 
imaging of EB3-GFP transfected human CH7C17 T cells treated with DMSO or MLN8237 and 
platted onto anti-CD3/CD28 stimulating antibodies (time 0s). (d) Distance from the T cell MTOC 
to the APC contact area in conjugates of T cells with SEE-pulsed APCs from three independent 
experiments (10 min; n=166 in DMSO, n=168 in MLN8237; 30 min; n=412 in DMSO, n=394 in 
MLN8237). Data represent means ± SD from 3 independent experiments. Means were compared 
with a t-test. 
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cells (Fig.  R9a and b). Despite the effect of Aurora A-depletion on MT dynamics, no significant 
change on MTOC translocation was detected in mouse CD4+ T cells (Fig.  R9b).  
 
 
As control, to determine if the percentage of J77 T cells conjugated with SEE-pulsed Raji is 
affected by Aurora A inhibition, we incubated J77 cells pretreated or not with the MLN8237 inhibitor 
with Raji cells during 30 min. Targeting of Aurora A did not alter the number of conjugates formed 
with SEE-pulsed Raji cells (Fig.  R10), indicating that inhibition of Aurora A did not result in a global 
defect in cytoskeleton dynamics.  
 
 
4.3 Aurora A in CD3ζ-bearing vesicles traffic at the IS 
 
In order to analyze the accumulation of TCR/CD3 complexes at the IS, Jurkat T cells pre-treated or not 
with the Aurora A inhibitor were conjugated with non stimulated or SEE- pulsed Raji cells during 30 min. 
The impaired MT growth observed in Aurora A-targeted T cells did not affect the localization of the surface 
Figure R9. Aurora A gene 
ablation does not affect the 
MTOC translocation to the IS. 
(a) Orthogonal and 3D projection 
from XYZ-stacks of WT and KO 
mouse cells, pre-treated with 
DMSO or MLN8237 (time 0s). 
Dotted white or red line indicates 
contact with substrate or media in 
the 3D projection, respectively.  
(b) Ratio of the MTOC location 
from the IS-like from three 
independent experiments (n=26 in 
WT, 22 in KO and WT+MLN and 
n=20 in KO+MLN). Data 
represent means ± SD. Means 
were compared with a Mann-
Whitney test. n.s., non-significant. 
(* p < 0.05), (** p < 0.01). 
Figure R10. Aurora A blockade does not affect the percentage 
of conjugates formation. Quantification of the percentage of T 
J77 T cells, pre-treated with DMSO or MLN8237, conjugated with 
SEE-pulsed Raji B cells, from three independent experiments. 
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TCR/CD3 complexes at the IS, since TCR/CD3ɛ was comparably clustered at the IS of untreated and 
MLN8237-treated T cell (Fig. R11a and b).  
 
We next assessed the dynamics of CD3ζ-bearing vesicles at the IS. CD3ζ traffics through 
endosomal compartments towards the IS (Yudushkin & Vale, 2010). These vesicles move associated to 
microtubules and support the sustained activation of the T cell at the IS (Martin-Cofreces et al, 2012; Soares 
et al, 2013a). The vesicles enter and leave the TIRF plane, some of them moving toward the position of the 
centrosome at the center of the IS-like structure, probably along the microtubules. To analyze the dynamics 
of these vesicles, Jurkat T cells expressing CD3-Cherry were treated with DMSO or MLN8237, settled 
onto anti-CD3/CD28, and analyzed by TIRFm. Images were taken every 100 ms (200 nm penetrance) and 
the trajectories of detected vesicles were tracked. Treatment of EB3 cells with MLN8237 decreased the 
number of vesicles at the IS-like structure and disrupted the movement of those that were present (Fig.  
R12a and b and Supplementary Movies 7 and 8). Moreover, the number of vesicles at the IS-like structure 
and their movement is also disrupted in Aurora A KO mouse CD4+ T cells (Fig. R12c and d and 
Supplementary Movie 9). The effect of Aurora A inhibition on microtubule dynamics therefore impeded 
the movement of vesicles toward the IS structure, a finding confirmed by the reduced speed of vesicles.  
 
 
 
Figure R11. Accumulation of TCR/CD3ε at the IS is not affected by Aurora A inhibition. (a) 
Maximum Z projections of confocal stacks of Jurkat T cells pretreated with vehicle (DMSO) or Aurora 
A inhibitor (MLN8237) and conjugated with SEE-pulsed Raji B cells. Cells were incubated for 30 
min, fixed, and stained for α-tubulin (green) and TRC/CD3ε (magenta). The right-hand image shows 
CMAC cell tracker labeling of Raji B cells (cyan) and bright field. Bar, 10 µm. (b) Graph shows 
quantification of TRC/CD3ε clustering at the IS from as in a from three independent experiments. 
Means ± SD is shown. t-test was used to compare means (n=101 in DMSO and in MLN8237). 
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Figure R12. Trafficking of CD3-bearing vesicles at the IS is impaired by Aurora A chemical 
inhibition or gene ablation. (a) Map of the trajectories of CD3ζ-cherry bearing vesicles in human 
CH7C17 T cells pre-treated with vehicle (DMSO) or MLN8237 inhibitor and settled on corresponding 
anti-human or anti-mouse stimulating anti-CD3/CD28-coated glass-bottom chambers. Images were 
taken every 100 ms under a TIRF microscope at a penetrance of 200 nm with 561 nm laser; vesicles 
were tracked with Imaris software over 60 s and maximal projections of the time-lapse are shown for 
tracks. A representative cell is shown for each case. Fluorescence images from CD3ζ-mCherry are 
also shown. (b) Quantification of the number of vesicle tracks, as well as the speed of vesicles from 
cells analyzed in a from three independent experiments (n=28 in DMSO, n=39 in MLN8237). (c) Map 
of the trajectories of CD3ζ-cherry bearing vesicles in Aurora A-deficient and control CD4+ T cells and 
settled on corresponding anti-human or anti-mouse stimulating anti-CD3/CD28-coated glass-bottom 
chambers. Images were taken every 110 ms under a TIRF microscope at a penetrance of 200 nm with 
561 nm laser; vesicles were tracked with Imaris software over 30 s and maximal projections of the 
time-lapse are shown for tracks. A representative cell is shown for each case. Fluorescence images 
from CD3ζ-mCherry and EB3-GFP are also shown. (d) Quantification of the number of vesicle tracks, 
as well as the speed of vesicles from cells analyzed in c from three independent experiments (n=16 in 
WT, n=17 in KO, n=19 in WT MLN8237, n=12 in KO MLN8237). Data represent means ± SD. Means 
were compared with a Mann-Whitney Test. n.s., non-significant. (* p < 0.05), (** p < 0.01), (*** p < 
0.001), (**** p < 0.0001).  
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4.4 Aurora A in TCR-driven actin dynamics 
 
To further analyze the role of Aurora A in the control of cytoskeletal dynamics at the IS, we assessed 
the effect of Aurora A inhibition on the activation-dependent interaction of TCR/CD3 with the actin-
cytoskeleton associated protein Nck. This interaction is enabled by the conformational change in the 
TCR/CD3ɛ complex upon antigenic triggering (Gil et al, 2002). Aurora A inhibition had no effect on CD3ζ-
Nck association in pull down assays (Fig.  R13a). This is in agreement with a surface recruitment and 
accumulation of TCR/CD3ɛ to the IS in Aurora A-inhibited cells (Fig R11a and b). Using a similar 
approach, we assessed whether Aurora A impairment affects the activation of the small GTPase Rac1, a 
hallmark for TCR-dependent actin polymerization (Gomez & Billadeau, 2008). Likewise, no effect was 
detected in Rac1 pull-down assays with the GST-PAK-CD (p21-activated kinase CRIB-Domain (Sander et 
al, 1998)) in stimulated CD4+ T cells when using MLN8327 inhibitor (Fig.  R13b).  
 
Furthermore, the Aurora A inhibitor did not affect the spreading of mCherry-β-actin-expressing T 
cells on anti-CD3/CD28-coated coverslips, measured either as the total occupied surface or as the rate of 
membrane extension on the coverslip (Fig.  R14a and b). This finding correlated with a similar distribution 
of mCherry-β-actin at the pSMAC and cSMAC in control and Aurora A-inhibited cells. Aurora A inhibition 
also had no effect on the total area occupied by adhered cells or their lamellae (Fig.  R14b). Similarly, actin 
accumulation at the IS in Jurkat T cell-Raji conjugates was not significantly affected by inhibition of Aurora 
A (Fig.  R14c and d).  
 
 
Figure R13. Aurora A inhibition does not affect actin cytoskeleton dynamics. (a) Immunoblot of 
a pull-down assay of GST-Nck fusion protein from cell lysates of control (DMSO; vehicle) or Aurora 
A inhibitor (MLN8237)-pretreated human T lymphoblasts. Activation was performed with soluble 
anti-CD3ε antibodies for indicated times. CD3ζ and GST are shown. CD3ζ content in whole cell 
lysates is indicated in the bottom row. (b) Immunoblot of Rac1 pull-down assay of GST and GST-
PAK-CD from cell lysates of DMSO or MLN8237-pretreated Jurkat T cells activated with SEE-pulsed 
Raji B cells (APCs) for the indicated times. Loading control for Rac1 in whole cell lysates is shown. 
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Figure R14. Actin spreading and distribution during the IS is not affected by Aurora A 
inhibition. (a) Images from TIRFm time-lapse analysis of mCherry-β-Actin-expressing Jurkat T cells 
spreading over anti-CD3/CD28-coated glass-bottom chambers. Cells were pretreated with DMSO or 
MLN8237. Images were taken every 100 ms for 5 min at 90 nm penetrance. A corresponding bright 
field image is shown. Bar, 10 µm. (b) Quantification of the area occupied by the whole cell (lamella), 
the actin-rich area (pSMAC), the central area (cSMAC), and the distribution of mean fluorescence 
intensity per area (ratios cSMAC:cell; pSMAC:cell and cSMAC/pSMAC) from cells in a from three 
independent experiments  (n=48 and n=36). Cells were fixed after spreading (4 min) and fluorescence 
images were taken. Data represent means ± SD. Means were compared with a t-test. (c) Maximum Z 
projections of confocal stacks from DMSO- or MLN8237-pretreated Jurkat T cells conjugated with 
SEE-pulsed Raji B cells. Cells were incubated for 30 min, fixed, and stained for α-tubulin (green) or 
actin (magenta). The right-hand image shows CMAC cell tracker labeling of APCs (cyan) and bright 
field. Bar, 10 µm. (d) Quantification of actin accumulation at the IS contact area in conjugates as in c 
from three independent experiments (n=100). Data represent means ± SD. Means were compared with 
a t-test.  
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We therefore analyzed the formation of the actin ring in mCherry-β-actin-expressing Jurkat T cells-
Raji conjugates using time lapse 3D confocal imaging. Actin accumulation and ring formation was similar 
in control and MLN8237-treated cells (Fig.  R15a and b and Supplementary Movie 10). Aurora A therefore 
appears to specifically affect the tubulin cytoskeleton at the IS, without affecting actin-based dynamics.  
 
4.5 Aurora A in early TCR signalling 
 
To assess the possible role of Aurora A in TCR signaling, we analyzed the phosphorylation of several 
canonical downstream molecules that are phosphorylated in response to cognate interactions in SEE-
stimulated Jurkat T cells (Fig.  R16a and b). The phosphorylation of specific residues in CD3ζ (Y83), LAT 
(Y132), PLCγ1 (Y783), PKCθ (T538) and ERK1/2 (T202/Y204) was greatly diminished upon Aurora A 
inhibition with MLN8237.  
Figure R15. Inhibition of Aurora A does not affect actin accumulation at the IS. (a) Image 
sequence for IS formation between mCherry-β-actin-expressing T cells and SEB-APCs treated with 
DMSO or MLN8237. XYZ-stacks were acquired every 25 s (Maximal projections of XYZ-stacks and 
3D reconstructions with Imaris Software are shown; a representative experiment out of 5 is shown). 
(b) Ratio of T cells forming lamella upon contact with an APC from a from three independent 
experiments. Data represent median ± interquartile range.  Medians were compared with a Mann-
Whitney test (DMSO: 28 cells (n=4); MLN8237: 25 cells (n=3)). n.s., non-significant. 
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To corroborate these results in primary CD4+ T cells, we analyzed the phosphorylation of those proteins 
through the activation with anti-CD3/CD28-coated beads (Fig.  R17a and b). The phosphorylation of 
specific residues was also greatly diminished upon Aurora A inhibition with MLN8237.  
 
 
 
 
Figure R16. Aurora A inhibition impairs TCR signaling pathways in Jurkat T cells. (a) 
Immunoblots showing phosphorylation of the indicated molecules in lysates of J77 Jurkat T cells 
pretreated with vehicle (DMSO) or Aurora A inhibitor (MLN8237) and conjugated for the indicated 
times with SEE-pulsed Raji B cells. (b) Quantification of blots as in a from four-six independent 
experiments. Error bars represent interquartile range. Medians were compared with a Friedman test.   
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The role of Aurora A in TCR signaling was also confirmed in a MHC/peptide-specific system, in 
which MLN8237-treated CH7C17 Jurkat T cells were stimulated with Hom2 lymphoblastoid B cells pre-
loaded with HA peptide (Fig.  R18a and b).  
 
In order to ascertain that the inhibitor was dose-dependent, Jurkat T cell pre-treated with DMSO or 
with different concentrations of MLN8237 during 30 min were incubated with SEE-preloaded Raji B cell 
during 10 min (Fig.  R19a and b). The results showed that TCR impairment was bigger at higher 
concentration of MLN8237 inhibitor, confirming that the inhibition of Aurora A is dose dependent. 
 
 
Figure R17 Aurora A inhibition impairs TCR signaling pathways in primary CD4+ T cells. (a) 
Immunoblots showing phosphorylation of the indicated molecules in lysates of DMSO- or MLN8237-
pretreated primary human CD4+ T cells conjugated for the indicated times with anti-CD3/CD28-
coated beads. (b) Quantification of blots as in a from four-six independent experiments. Error bars 
represent interquartile range. Medians were compared with a Friedman test (* p < 0.05). n.s., non-
significant. a.u., arbitrary units.   
 
Figure R18. Aurora A inhibition impairs TCR signaling in a MHC/peptide-specific system. (a) 
Immunoblots showing phosphorylation of the molecules indicated in lysates of CH7C17 Jurkat T cells 
pretreated with DMSO or MLN8237 and conjugated for the indicated times with HA-peptide-pulsed 
Hom2 B cells. (b) Quantification of blots as in a from four-six independent experiments. Error bars 
represent interquartile range. Medians were compared with a Friedman test (* p < 0.05). n.s., non-
significant. a.u., arbitrary units. 
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As a control of MLN8237 specificity, we added the inhibitor just before the activation of  Jurkat T 
cells with SEE-Raji cells and the same effect was observed (Fig.  R20).  
 
 
 
 
 
 
 
 
 
 
Figure R19. Dose-response effect of the Aurora A inhibitor MLN8237 on T cell activation.  (a) 
Immunoblots showing phosphorylation of the indicated molecules in lysates of J77 Jurkat T cells 
pretreated with vehicle (DMSO) or Aurora A inhibitor (MLN8237) at the concentrations indicated 
and conjugated for 10 minutes with SEE-pulsed Raji B cells. (b) Quantification of blots as in a from 
three independent experiments. Error bars represent interquartile range. 
 
 
Figure R20. Addition of MLN8237 
just before T cell activation impairs 
TCR signaling. Immunoblots showing 
phosphorylation of the indicated 
molecules in lysates of J77 Jurkat T 
cells conjugated for the indicated times 
with SEE-pulsed Raji B cells in 
presence of DMSO or MLN8237. 
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By extensively washing the inhibitor before activation, the phosphorylation levels of these specific 
residues were restored, indicating that the effects of the inhibitor were reversible (Fig.  R21).  
 
 
 
 
 
 
 
 
MLN8237 shows a 200 fold higher selectivity for Aurora A over Aurora B (Manfredi et al, 2011); 
nonetheless, to rule out a possible role of Aurora B, we treated Jurkat T cells with AZD1152 (100 nM), 
which is 3,700 times more selective for Aurora B (Yang et al, 2007). AZD1152 had no effect on the 
phosphorylation of T cell proteins (Fig.  R22), confirming that proper T cell activation critically depends 
of the isoform A, but not B, of Aurora kinase.  
 
 
 
 
This was further confirmed in conjugates of Aurora A-silenced Jurkat T cells and SEB-preloaded 
Hom2 B cells as APCs. The activation of CD3ζ-dependent molecules was defective in Aurora A-silenced 
cells, with below-normal LAT phosphorylation on residue Y132, likely responsible for the concomitant 
decreases in PLCγ1 (Y783) and PKCθ (T538) phosphorylation (Fig. R23).  
Figure R21. MLN8237 is a 
reversible inhibitor. Immunoblots 
showing phosphorylation of the 
indicated molecules in lysates of J77 
Jurkat T cells pretreated with DMSO 
or MLN8237 for 30 min, extensively 
washed and conjugated for the 
indicated times with SEE-pulsed Raji 
B cells. 
 
Figure R22. TCR signaling is not 
affected by Aurora B inhibition. 
Immunoblots showing phosphorylation 
of the indicated molecules in lysates of 
J77 Jurkat T cells pretreated with vehicle 
(DMSO) or Aurora B inhibitor 
(AZD1152, 100 µM) and conjugated for 
the indictaed times with SEE-pulsed Raji 
B cells.  
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To determine the role of Aurora A in late events of T cell activation, we examined the mRNA 
expression of IL-2, CD25 and CD69. Human CD4+ T lymphocytes were treated with MLN8237 and 
AZD1152 or vehicle for 30 min, and stimulated with anti-CD3/CD28 antibodies for 3 h. Inhibition of 
Aurora A impaired the up-regulation of IL-2, CD25 and CD69 mRNA determined by RT-PCR (Fig.  R24), 
indicating a defect in late T cell activation. In contrast, Aurora B inhibition had no effect on the mRNA 
production of these genes, supporting a specific role for Aurora A and its regulated pathways in T cell 
activation. 
 
 
 
Pharmacologic inhibition of Aurora A also impaired early T cell activation in mouse naive CD4+ T 
cells polyclonally stimulated with anti-CD3/CD28 (Fig.  R25).  
Figure R23. TCR signaling is impaired by silencing of Aurora A. (a) Immunoblot analysis of 
Aurora A protein expression in Jurkat T cells transfected with a specific siRNA against Aurora A 
(siAUA) or a scrambled negative control (siControl). (b) Immunoblots showing phosphorylation of 
the indicated molecules in lysates of J77 Jurkat T cells transfected with the siAUA or siControl and 
conjugated for the indicated times with SEE-pulsed Raji B cells. 
 
Figure R24. IL2, CD69 and CD25 expression 
is impaired by Aurora A inhibition.  IL2, CD69 
and CD25 mRNA levels in primary human CD4+ 
T cells pretreated with DMSO, MLN8237 (10 
µM) or the Aurora B inhibitor AZD1152 (100 
nM) and activated by settling on anti-CD3/CD28-
coated plates for 4 h. mRNA levels from four-six 
independent experiments were normalized to the 
housekeeping gene GAPDH and the levels of the 
target mRNA in non-stimulated cell levels. Error 
bars represent interquartile rage. Medians were 
compared with a Mann-Whitney test. (** p < 
0.01). 
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To further assess the function of Aurora A in primary naive T cells, we deleted Aurora A expression 
in CD4+ cells from the conditional Aurora KO mice and activated them with anti-CD3/CD28 antibodies. 
Tamoxifen-induced suppression of Aurora A expression in Aurka(lox/lox); RERT(ert/ert) cells correlated 
with clear decreases in the phosphorylation of CD3ζ (Y83), LAT (Y132), PLCγ1 (Y783), PKCθ and 
ERK1/2 (T202/Y204) (Fig.  R26a and b).   
 
In complementary experiments, we examined a transgenic mouse model of Aurora A overexpression 
(Piazzolla et al, 2014). Naive CD4+ T cells isolated from lymph nodes and spleens of Col1a1tetO-Aurka/+; 
Rosa26rtTA/rtTA mice (Aurora KI) and controls were treated with doxycycline and IL-7 for 24 h, followed 
 
Figure R26. Aurora A gene ablation blocks TCR signaling pathways. (a) Immunoblots showing 
phosphorylation of the indicated molecules in cell lysates of Aurora KO and control CD4+ T cells 
conjugated for the indicated times with anti-CD3/CD28 antibodies. (b) Quantification of data from 
four independent experiments as in a. Error bars represent interquartile range. Medians were compared 
with a Friedman test (* p < 0.05). n.s., non-significant. a.u., arbitrary units. 
 compared with a Mann-Whitney test. (** p < 0.01). 
Figure R25. Aurora A inhibition 
impairs TCR signaling in mouse 
CD4+ T cells. Immunoblots showing 
phosphorylation of the indicated 
molecules in cell lysates of WT mouse 
CD4+ T cells pretreated with vehicle 
(DMSO) or Aurora A inhibitor 
(MLN8237) and activated for the 
indicated times with anti-CD3/CD28 
antibodies. 
B cells.  
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by activation with anti-CD3/CD28 antibodies. Doxycycline treatment increased Aurora A expression in the 
conditionally transgenic cells (Fig.  R27a), correlating with increased levels of TCR-dependent signaling 
(Fig.  R27b and c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.6 Mechanism through Lck regulation  
 
To study the mechanism underlying the earliest T cell activation defects in the absence of Aurora A, 
we assessed the possible regulation of the Src kinase Lck by Aurora A. Lck phosphorylates CD3 ITAMs at 
tyrosine residues upon TCR trigering and shows autophosphorylation activity towards its Y394 residue, an 
activatory residue (Nika et al, 2010).  By quantitative analysis of Lck accumulation at the IS we have 
detected a significant reduction in Lck relocation to the IS contact area, as a result of Aurora A inhibition 
in Jurkat T cells (Fig.  R28a and b). In accordance with a perturbed Lck localization, pharmacologic 
inhibition of Aurora A in human primary CD4+ T cells impaired Lck autophosphorylation at Y394, a marker 
of its activity (Fig.  R28c and d). Notably, these experiments showed that Lck-Y394 phosphorylation was 
impaired prior to TCR stimulation, suggesting a role of Aurora A in the maintenance of the pre-activated 
pool of Lck (Nika et al, 2010).  
Figure R27. Overexpression of Aurora A increase levels TCR molecules phosphorylation.  (a) 
Immunoblot analysis of Aurora A protein expression in CD4+ T cells isolated from Col1a1tetO-
Aurka/+; Rosa26rtTA/rtTA mice and treated with doxycycline for 20 h to induce Aurora A expression 
(KI). Control cells (WT) were maintained without doxycycline. Actin is shown as a loading control. 
(b) Immunoblots showing phosphorylation of the indicated molecules in cell lysates of Aurora KI 
CD4+ T cells conjugated for the indicated times with anti-CD3/CD28 antibodies. (c) Quantification of 
data from four independent experiments as in b. Error bars represent interquartile rage. Medians were 
compared with a Friedman test (* p value < 0.05). n.s., non-significant. a.u., arbitrary units. 
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To analyze whether the effect of Aurora A on Lck activation is dependent on the intracellular traffic 
of Lck (Soares et al, 2013a) and taking into account that Lck recruitment at the IS is also driven by its 
association with CD4 (Li et al, 2004), we decided to assess T cell activation in a Lck-deficient cell line 
(J.CAM1 (Goldsmith & Weiss, 1987; Straus & Weiss, 1992) ) reconstituted with full-length Lck-GFP or 
murine CD4-Lck chimeric proteins. CD4-Lck is mainly localized at the plasma membrane (Anton et al, 
2008; Xu & Littman, 1993) .  A murine CD4 lacking its cytosolic tail and fused to GFP was used as a 
negative control (Krummel et al, 2000) (Fig.  R29; CD4-ΔCyt-GFP). We found that Lck-GFP expression 
rescued CD3 phosphorylation and thus T cell activation in J.CAM1, whereas MLN8237 treatment 
prevented such an effect. Rescue of J.CAM1 signaling with CD4-Lck chimaera was also prevented with 
the Aurora A inhibitor. Therefore, Aurora A activity is needed for Lck activity independently of its 
intracellular trafficking during IS formation. 
 
Figure R28. Aurora controls localization and phosphorylation of the tyrosine kinase Lck. (a) 
Maximum Z projection of XYZ-stack of human Jurkat T cells pretreated with vehicle (DMSO) or 
Aurora A inhibitor (MLN8237) and conjugated with SEE-preloaded Raji B cells (APCs; 30 min). 
Cells were fixed and stained for α-tubulin-FITC (green), PKCθ (magenta) and Lck (red). Bright field 
images are included. Bar, 10 µm. (b) Quantification of Lck accumulation at the IS in conjugates as in 
a from three independent experiments (n=96 in DMSO, n=94 in MLN8237). Data represent means ± 
SD. Means were compared with a t-test; (**** P<0.0001). (c) Immunoblot of Lck phosphorylation at 
Y394 in primary human CD4+ T cells. Cells were pretreated with DMSO or MLN8237 and conjugated 
for the indicated times with anti-CD3/CD28-coated beads. Total Lck and actin are included as loading 
controls. Arrows point Lck band. (d) Quantification of data from four independent experiments as in 
c. Error bars represent SD. Medians were compared with a Friedman test (* P<0.05). 
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Immunoprecipitation of Lck from T lymphoblasts followed by mass spectrometry analysis revealed 
that Aurora A inhibition resulted in decrease of Lck phosphorylation at the activation residue Y394 in 
resting and stimulatory conditions (Fig.  R30).  
 
 
 
 
 
 
  
 
 
 
 
This was further corroborated by in vitro kinase assays of purified recombinant Lck protein by 
immunoprecipitated Aurora A proteins. While wild type (WT) Aurora A protein keeps Lck phosphorylated 
at  residue Y394, a kinase dead mutant (KD) form of  Aurora is unable to maintain Lck phosphorylation at 
Y394 (Fig.  R31). Treatment with the Aurora A inhibitor corroborated the KD results (Fig.  R31). Together 
these results highlight the relationship of Aurora A-mediated signal spreading at the IS with Lck location, 
phosphorylation, and therefore, regulation. 
 
 
Figure R29. Membrane Lck is affected by Aurora A inhibition. Immunoblots of CD3ζ 
phosphorylation in lysates of J.CAM1 T cells transfected with Lck-GFP, CD4-Lck or CD4-ΔCyt-
GFP, pretreated with DMSO or MLN8237 and conjugated for 5 min with SEE-pulsed APCs. 
 
Figure R30. Lck phosphorylation at Y394 
decreases by Aurora A inhibition. T cell 
lymphoblasts pretreated with DMSO or 
MLN8237 were activated or not with SEE-
pulsed APCs (2 min) and subjected to 
immunoprecipitation using an anti-Lck 
antibody. The immunoprecipitates were 
subjected to mass spectrometry analysis. (a) 
MS/MS extracted ion chromatograms of the 
Y394-phosphorylated and non-modified 
forms of Lck peptide LIEDNEYTAR. (b) 
Phosphorylated:non-modified peak ratios.  
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Figure R31. Aurora A keeps Lck 
phosphorylated before TCR stimulation. 
Recombinant Lck was incubated with 
Aurora A WT (in the absence or presence of 
MLN8237) or Aurora A KD 
immunoprecipitated from nocodazole-
treated (16 h), transfected HEK293 cells. 
Lck and Aurora were incubated for 30 min 
in presence of ATP and the mixture 
analyzed by mass spectrometry. (a) MS/MS 
extracted ion chromatograms of the Y394-
phosphorylated and non-modified forms of 
Lck peptide LIEDNEYTAR. (b) 
Phosphorylated:non-modified peak ratios.  
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5. Discussion 
 
In this study we have analyzed the influence of a well-known cell cycle regulator, Aurora A 
kinase, in T cell activation. Our results provide novel evidence that Aurora A is a key regulator of 
early TCR-dependent signaling pathways and controls signaling vesicle and microtubular dynamics. 
However, the direct interaction of TCR/CD3 with Nck and actin polymerization at IS are not affected 
by Aurora A inhibition. Aurora A localizes at the IS and appears activated upon antigen- and 
superantigen-driven T cell activation. Early activation of Aurora A seems to be essential for TCR 
downstream signaling leading to LAT and PLC activation. In addition, our data provide mechanistic 
insight into how Aurora A acts as master regulator of T cell activation by controlling Lck 
phosphorylation and clustering at the IS.  
 
5.1 Aurora A localization and activation at the IS 
 
During CD4+ and CD8+ T cell activation, the secretory elements, including the GA, ER 
(endoplasmic reticulum), endolysosomal system and secretory vesicles are rapidly translocated with 
the centrosome to the IS (Bustos-Moran et al, 2016; Martin-Cofreces et al, 2014). This specific 
localization promotes a fast and direct secretion of diverse molecules from the trans-Golgi network 
(TGN) and the endosomal compartment to the plasma membrane, regulating the polarized secretion 
of exosomes or IL-4 cytokine in CD4+ and perforin and granzymes from lytic granules in CD8+ T cells 
(Bustos-Moran et al, 2016; Huse et al, 2008; Kienzle & von Blume, 2014). Several studies have 
proposed a relationship between GA and Aurora A function and localization. During mitosis, the GA 
undergoes fragmentation to properly segregate into the daughter cells. The inhibition of the GA 
fragmentation at the G2 stage blocks the recruitment and activation of Aurora A at the centrosomes 
(Cervigni et al, 2011). Also, there is evidence of a role for the GA in the regulation of spindle formation 
during mitosis. The GA matrix protein GM130 recruits importin α to the GA membranes, promoting 
the release of the spindle assembly factor TPX2. TPX2 activates Aurora A, stimulating local MT 
nucleation (Fig. D1) (Wei et al, 2015). GM130 may control MT polymerization from the GA also in 
cells in interphase. To do this, it recruits AKAP450 to the cis-Golgi (Rivero et al, 2009). AKAP450 
promotes tubulin nucleation through the binding to CGP subunits of the γ-Tubulin ring complex (γ-
TURC) at the centrosome (Takahashi et al, 2002), which seems a shared mechanism for 
polymerization at the cis-Golgi. The structure of MTs is clearly different at the centrosome and the 
GA, since they show a radial array in the first organelle and a more tangential disposition at the GA 
(Zhu & Kaverina, 2013). In this regard, silencing of AKAP450 or over-expression of a dominant-
negative, AKAP450-centrosomal domain prevents T cell activation and centrosome polarization to the 
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IS (Robles-Valero et al, 2010). Therefore, centrosome-resident AKAP450 is required for T cell 
activation, but the relative contribution of GA-resident AKAP450 remains to be determined. Although 
Aurora A inhibition does not prevent centrosome polarization, tubulin nucleation is impaired. The 
possible tubulin-nucleation activity of the GA has not been determined in T cells. Since Aurora A is 
activated by TPX2 and this process is mediated by GM130 during spindle formation in mitosis, these 
observations indicate that Aurora A could be involved in MT polymerization from the GA during the 
IS, further supporting a conserved mechanism between cell division and IS formation (Fig. D1). 
A recent study showed that, during G2 phase, the GA fragmentation promotes Src protein 
activation at the TGN. This is relevant because Src phosphorylates Aurora A on residue Y148; which 
is required for Aurora A to localize to centrosomes and become active (Fig. D1a) (Barretta et al, 2016). 
Therefore, the translocation of the GA during the first step of the IS might be involved in the activation 
of Aurora A in this region. Some proteins that regulate Aurora A function in other systems, e.g. TPX2 
or Src, which also participate in the formation of the IS, may form feedback loops that connect the 
regulation of different phenomena, e.g. activation of Aurora A by Src during mitosis and Lck 
regulation by Aurora A during the IS (Fig. D1). 
Some works reveal a non-mitotic role for Aurora A, such as ciliary disassembly, with different 
mechanisms of activation. This process requires interaction with Ca2+/calmodulin (CaM) (Plotnikova 
et al, 2012). The IS formation has been compared with the cilia formation, since a set of proteins are 
implicated in both processes, such as IFT (intraflagellar transport) proteins for transport of vesicles, 
AKAP450 or HDAC6, both regulators of microtubules (Bustos-Moran et al, 2016). During the IS, Ca2+ 
release-activated channels (CRAC) are opened after TCR activation, promoting proper IS formation 
by regulating actin organization (Hartzell et al, 2016). Similarly to the relationship between Ca2+ and 
Aurora A activation in primary cilia formation, this interaction could imply a role of Ca2+ in Aurora A 
activation during IS formation. 
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Figure D1. Activation of Aurora A during the IS by proteins from GA. (a) Regulation of 
Aurora A activity during G2 phase. (1) Interaction of GM130 with importin α promotes the release 
of TPX2 and the consequent Aurora A autophosphorylation, promoting local MT polymerization. 
(2) Aurora A phosphorylation by Src allows Aurora A localization at the centrosome for proper 
centrosomal maturation. (b) Possible model of Aurora A regulation during the IS. (1) 
Translocation of vesicles containing Lck from TGN to membrane is directed by MAL. (2) 
Activation of Aurora A by TPX2 release next to the IS area. (3) Local MT polymerization from 
GA through Aurora A activation mediated by GM130 and AKAP450. (4) Activation of Aurora A 
at the centrosome through Src activation. GA, Golgi apparatus; Imp α, importin α; MT, 
microtubule; TCR, T cell receptor; TGN, trans-Golgi network. 
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5.2 Microtubule polymerization and vesicular traffic 
 
Aurora A contributes to centrosome maturation through the recruitment of MT nucleation factors. 
However, its absence does not prevent the formation of the centrosomal microtubule aster but instead 
affects the density of the aster formed in other systems (Sardon et al, 2008). Our TIRFm analysis 
demonstrates that Aurora A controls growing MT arising from the MTOC upon TCR activation while 
having no apparent effect on MTOC translocation at the IS. In addition, during the M phase Aurora A 
is required for the recruitment of adaptor proteins like NEDD1 for the correct formation of the mitotic 
spindle. Previous work on proteins implicated in MT regulation such as EB1 or HDAC6 (Martin-
Cofreces et al, 2012; Serrador et al, 2004) showed a defect in late T cell activation. The role of these 
proteins in MT cytoskeleton dynamics and T cell activation seemed to be mainly related to the 
maintenance of the TCR signal rather than its initial activation. Aurora A might regulate late T cell 
activation through a similar mechanism. Our data indicate that the decrease in the number of MTs 
nucleated near the contact area may affect polarized secretion from this area and vesicular trafficking 
at the IS and throughout the T cell. Hence, Aurora A inhibition prevents movement of CD3ζ vesicles 
around the MTOC almost completely, possibly reflecting a global effect on vesicle trafficking. Also, 
since CD3 is tightly regulated by its cycle of degradation and recycling (Monjas et al, 2004), the 
absence of this pool of CD3ζ vesicles at the c-SMAC may explain why the TCR signal cascade is not 
properly propagated. It has been proved that there is a pool of phosphorylated CD3ζ that instead of 
going to a degradation pathway keeps accumulated at the endosomal compartment ready to maintain 
CD3ζ phosphorylation signaling (Yudushkin & Vale, 2010). Although Aurora A inhibition has no 
effect in TCR/CD3ε subunit surface clustering at the IS, the transport of vesicles of the CD3ζ subunit 
is clearly impaired. Taking into account the presence of this phosphorylated CD3ζ pool at the 
endosomal compartment, Aurora A might have an effect mainly over this recycling of the active CD3ζ 
and therefore over TCR signal propagation. 
 
5.3 Actin cytoskeleton 
 
Although Aurora A contributes to actin cytoskeleton dynamics in mitosis and during mammary 
cell migration, no such effect was observed during IS formation by spreading T cells. Aurora A-
mediated phosphorylation of LIM kinase 1 (LIMK1) at the centrosomes in prophase is essential for 
modulation of actin filaments and subsequent spindle formation. LIMK1 acts by inactivating the 
phosphorylation of the actin depolymerizing family protein cofilin, thus stabilizing the cortical actin 
network during spindle orientation (Ritchey et al, 2012). In mammary cell migration Aurora A 
promotes increased expression of the cofilin phosphatase SSH1, resulting in cofilin activation and 
actin reorganization and migration (Wang et al, 2010). However, our data show that Aurora A 
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inhibition affects neither actin accumulation during IS formation nor cell spreading. Indeed, we found 
that Aurora A-inhibited T cells form normal-shaped lamellae. During IS formation, Nck acts as a 
bridge between the TCR activation and actin cytoskeleton reorganization at the IS. When the TCR 
recognizes a specific antigen, a conformational change in the CD3 chain unmasks a neoepitope to 
which Nck binds, leading to transmission of the activation signal through the actin cytoskeleton (Gil 
et al, 2002). CD3-NcK association is not affected by Aurora A inhibition, a finding in accordance 
with the absence of changes in actin accumulation at the IS in MLN8237-pretreated T cells. Moreover, 
this is consistent with the observed accumulation of the TCR/CD3 complex at the IS, by the tracking 
forces exerted by actin (Comrie & Burkhardt, 2016).  
 
5.4 Early T cell activation 
 
Our results show regulatory effects of Aurora A on early and late T cell signaling. Inhibition of 
Aurora A abrogates proper T cell activation determined by the phosphorylation profile of TCR-
signaling proteins such as CD3 and the adapter proteins and kinases LAT, PLCγ1 and PKCθ. These 
effects on TCR pathway phosphorylation events were observed in response to the Aurora A inhibitor 
MLN8237 and Aurora A gene ablation in mouse T cells, indicating that this is a specific consequence 
of Aurora A inhibition. The initial activation of T cells occurs at the plasma membrane, but its 
continued progress requires the contribution of intracellular components such as the MTOC and the 
MT-dependent vesicular traffic and mitochondrial activity (Martin-Cofreces et al, 2014). Aurora A 
thus contributes to the propagation of TCR activation to the intracellular compartment, leading to 
activation of genes such as IL-2, CD69 and CD25. Moreover, the strength of T cell activation can 
determine the ability of T cells to divide asymmetrically, thereby promoting functional differentiation 
into subpopulations of T cells that regulate the immune response (King et al). Our data suggest that T 
lymphocytes defective in Aurora A do not become properly activated, possibly affecting the outcome 
of the adaptive immune response.  
 
However, neither the defect on MT dynamics nor the impairment in CD3ζ vesicles transport can 
explain the blockade of the initial trigger of TCR signaling. These early defects of CD3ζ-dependent 
signaling in Aurora A-targeted cells are more likely explained by altered activity of Src- kinases. This 
family includes Lck and Fyn, the first kinases to phosphorylate the ITAMs in CD3, which are required 
for full activation and signal transmission (Palacios & Weiss, 2004; Schoenborn et al, 2011).  Our data 
demonstrate that Lck location and phosphorylation are altered by chemical inhibition of Aurora A, 
demonstrating that Aurora A controls TCR pathways dependent on CD3-ITAM phosphorylation.  
 
 
 74 
 
DISCUSSION 
5.4.1 Direct Lck regulation by Aurora A 
 
During IS formation, Lck localizes near the TCR/CD3 complexes, which is required for 
Lck-mediated phosphorylation of CD3 immunoreceptor tyrosine-based activation motifs 
(ITAMs) (Palacios & Weiss, 2004). Lck appears in specific membrane microdomains (rafts) 
containing MAL and Caveolin-1 (Cav-1). These proteins are required for Lck clustering to the 
membrane during the IS, and MAL or Cav-1 depletion decreases the efficiency of CD3 ITAM 
motifs phosphorylation (Anton et al, 2008; Schonle et al, 2016). MAL is present in vesicles 
containing Lck, enabling the association of Lck with the plasma membrane at the IS (Fig. D2) 
(Martin-Cofreces et al, 2014). Since Aurora-A gene depletion or pharmacological inhibition 
impedes the proper traffic of CD3ζ-bearing vesicles to the IS, we postulated that Lck bearing 
vesicles traffic may also be affected by the absence of Aurora-A activity. Interestingly, Aurora A 
inhibition prevented the rescue of CD3 phosphorylation in a cell line lacking Lck (JCAM.1) 
transfected with a construction of full-length Lck fused to the transmembrane domain of CD4. In 
these cells, Lck-CD4 is localized at the IS in a vesicle-independent manner, suggesting that 
Aurora A may control the enzymatic activation of Lck that is already bound to the plasma 
membrane, and not only its localization (Fig. D2). 
Lck, and SFKs in general, are regulated reciprocally by phosphorylation and de-
phosphorylation of two conserved tyrosine residues (Palacios & Weiss, 2004). Lck is 
phosphorylated in residue Tyr394, which is used as a fiduciary marker of its activation. One study 
has shown that TCR activation does not control the phosphorylation level of Y394, suggesting 
that Lck is activated prior to T cell activation (Nika et al, 2010). Another study showed Lck to be 
regulated through conformational changes, clustering and spatio-temporal proximity to other 
proteins, e.g. the Lck inhibitory kinase Csk and the transmembrane phosphatase CD45.  Csk 
regulates the phosphorylation of residue Y505, which is inhibitory and CD45 dephosphorylates 
both Y505 and Y394 residues (Hui & Vale, 2014). However, other authors have reported an 
increase of nearly 20% in Lck phosphorylation upon TCR priming, as measured by Western blot 
after immunoprecipitation, or through FLIM-FRET analysis with a biosensor that detects 
conformational opening and closing (Stirnweiss et al, 2013). Aurora A inhibition decreases Y394 
phosphorylation before TCR triggering. Since Aurora A is a serine/threonine kinase, Y394 is not 
expected to be its substrate. In fact, Y394 is an autophosphorylation site (Palacios & Weiss, 2004). 
Based on these observations, a model can be drawn in which Aurora A phosphorylates a yet 
unidentified residue in Lck, which may in turn influence Y394 autophosphorylation by affecting 
the conformation of Lck (Fig. D2). 
Several Ser residues have been identified in Lck upon activation; mainly S59 at the unique 
N-terminal domain and S122, S158, S192 and S194 at the SH2 domain. S59 and S122 seem to 
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reduce Lck activity either in vivo or in vitro. In particular, S59 seems to act on the ability of the 
SH2 domain to interact with partners and it is phosphorylated during mitosis (Joung et al, 1995; 
Kesavan et al, 2002; Nguyen et al, 2016; Soula et al, 1993). However, the fact that Aurora A 
disruption decreases Lck activity points to other residues as substrates for this enzyme. Mass 
spectrometry analysis combined with the use of Aurora A conditional knock out mice could help 
us to identify other putative phosphorylatable sites on Lck. Moreover, FLIM-FRET and super-
resolution analyses would be a proper experimental strategy to assess the conformational changes 
that may occur in Lck protein and/or the possible partners of Lck during the IS. 
 
5.4.2 Lck indirect regulation by Aurora A 
 
Although Aurora A may be directly regulating Lck phosphorylation, it is feasible that 
additional protein(s) may serve as “interaction bridges” between Aurora A and Lck. Csk and 
CD45 appears as suitable candidates. Phosphorylation of Lck at Y505 by Csk promotes the 
intramolecular interaction of the residue with the SH2 domain, favoring a closed conformation of 
Lck (Fig. D3) (Xu et al, 2015). Hence, phosphorylation of Y505 prior to Y394 maintains Lck in 
a closed, inactive form, whereas phosphorylation of Y394 promotes Lck activation, even though 
Y505 is phosphorylated afterwards (Palacios & Weiss, 2004).  Moreover, CD45 dephosphorylates 
both residues in Lck and also CD3 ITAMs, although its effect is more noticeable in the ITAMs 
(Dustin, 2012; Hermiston et al, 2003; Hui & Vale, 2014). Aurora A could phosphorylate and 
Figure D2. Lck direct regulation by Aurora A. (1) Aurora A regulates the vesicular traffic of 
Lck trough the microtubule network. (2) Possible phosphorylation of Lck by Aurora A in an 
unknown residue promotes autophosphorylation in Y394 and proper translocation to the IS 
region. 
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inactivate Csk, and thus Lck Y505 phosphorylation, which would maintain Lck in an active 
conformation (Fig. D3). The described phosphorylation of Csk on S364 increases its activity, and 
therefore would not fit in this model (Vang et al, 2001). Csk is regulated by the phosphoprotein 
associated with glycosphingolipid-enriched microdomains/Csk binding protein (PAG/Cbp) 
complex, which is phosphorylated in lipid rafts in resting T cells, thereby inducing Lck inhibition. 
Phospho-PAG/Cbp promotes the binding of Csk to Lck and the phosphorylation of Y505 (Fig. 
D3) (Brdicka et al, 2000; Kawabuchi et al, 2000). After TCR triggering, dephosphorylation of 
PAG/Cbp in tyrosines leads to the dissociation of Csk from lipid rafts and allows Lck activation 
(Davidson et al, 2003). However, a recent study based on proteomic approaches has shown that 
an increase in PAG phosphorylation can be detected upon TCR activation, accompanied by Csk 
and SHIP1 and PTPN22 phosphatases interaction (Reginald et al, 2015). Hence, the absence of 
Aurora A could reinforce the PAG/Cbp interaction with Csk, enhancing Lck inhibition due to the 
phosphorylation of the PAG/Cbp complex. Therefore, Aurora A might be regulating the kinase 
that acts on PAG. These studies, together with the observed mislocalization of Lck at the IS in 
Aurora A-inhibited cells and the fact that non-phosphorylatable Aurora A cannot be properly 
recruited to the IS, suggest that Aurora A may spatio-temporally regulate the localization of other 
proteins involved in TCR activation (Fig. D3).  
The spatial localization of the phosphatase CD45 is essential for TCR activation. When the 
eye-shaped IS forms, CD45 is sterically excluded from the T cell-APC proximal contact area to 
prevent the dephosphorylation of CD3 and Lck (Varma et al, 2006). Interestingly, Aurora A 
inhibition decreased both Lck phosphorylation at Y394 and that of the CD3 ITAMs. However, 
although CD45 activity could explain the enhanced dephosphorylation of both residues in Aurora 
A depleted cells, the sterically exclusion model for CD45 makes unlikely for Aurora A to regulate 
its activity directly. 
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In summary, our results show that Aurora A plays an important role in the early events initiated 
upon TCR stimulation, and unravel a novel molecular mechanism that regulates early signaling and 
cytoskeletal and vesicle dynamics in T cells. The prevention of T cell activation by Aurora A inhibition 
has important clinical implications. Aurora A inhibitors are currently under evaluation for cancer 
therapy in Phase I-II clinical trials (Malumbres & Perez de Castro, 2014). In these trials, aggressive B-
Figure D3. Lck indirect regulation by Aurora A. In resting T cells, the PAG/Cbp complex 
bound to Csk promotes the binding of Csk with Lck, inhibiting it by the phosphorylation of Y505 
residue. The phosphatase CD45 is located at the IS region. During T cell activation (1) the 
PAG/Cbp complex promotes the release of Lck by Csk, activating it. Proper Aurora A localization 
at the IS could be regulating this mechanism through the phosphorylation of the PAG/Cbp 
complex or Csk directly. (2) After TCR triggering, the phosphatase CD45 is excluded from the 
IS. GA, Golgi apparatus; TCR, T cell receptor. 
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cell and T-cell non-Hodgkin lymphomas have shown an overall positive response, promoting new 
Phase III studies. It will be important to define the extent to which the new function reported here 
participates in these responses and to determine whether the T cell activation pathway can provide new 
biomarkers, critical for understanding these therapeutic effects. Very recently, a transcriptomic 
analysis points Aurora A as a targetable molecule for GVHD (Graft Versus Host Disease) prevention 
in a primate model (Furlan et al, 2015). Hence, our data provide a mechanistic explanation by how 
Aurora A controls T cell activation. Given the importance of Aurora A inhibitors in cancer therapy, 
these results may provide new opportunities for treating lymphocyte diseases such as GVHD, T-cell 
lymphomas or leukemias. 
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6. Conclusions 
 
The findings presented herein support the following conclusions: 
 
1) Antigenic T cell stimulation promotes Aurora A activation and localization at the immune 
synapse. 
 
2) Chemical inhibition or genetic ablation of Aurora A interrupt the microtubule growth and 
the dynamics of CD3-signaling vesicles at the immune synapse. 
 
3) Actin polymerization during the immune synapse formation is not altered by Aurora A 
inhibition. 
 
4) The pharmacological inhibition and the specific silencing of Aurora A impair early TCR 
signalling pathway. 
 
5) Chemical inhibition of Aurora A decreases the expression of IL-2, CD69 and CD25. 
 
6) The activity and the location of the tyrosine kinase Lck is controlled by Aurora A for proper 
T cell activation. 
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7. Conclusiones 
 
Los resultados presentados en esta tesis doctoral son compatibles con las siguientes conclusiones: 
 
1) La estimulación antigénica de linfocitos T promueve la activación y la localización de Aurora 
A en la sinapsis inmune. 
 
2) La inhibición farmacológica y la interrupción genética de Aurora A bloquean el crecimiento 
de microtúbulos y la dinámica de vesículas de señalización de CD3 en la sinapsis inmune. 
 
3) La polimerización de actina durante la formación de la sinapsis inmune no se afecta por la 
inhibición de Aurora A. 
 
4) La inhibición química de Aurora A y su silenciamiento específico bloquean la ruta de 
activación del TCR. 
 
5) La inhibición de Aurora A disminuye la expresión de IL-2, CD69 y CD25. 
 
6) Aurora A regula la actividad y la localización de la tirosina quinasa Lck, necesaria para una 
correcta activación del linfocito T. 
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9. Annexes 
9.1 Supplementary information 
 
- Supplementary Movie 1. 4D imaging of Microtubule growing in control and Aurora 
A-inhibited Jurkat cells. Control Jurkat T cells transfected with EB3-GFP were pre-
treated with MLN8237 or vehicle, allowed to settle on stimulatory anti-CD3/CD28-
coated surfaces and recorded under a confocal microscope. Fluorescence and bright field 
images for XYZ-stacks were taken every 1.2 s. MLN8237 or vehicle was present in the 
imaging medium. Movie was mounted at 10 fps. 
 
- Supplementary Movie 2. 4D imaging of Microtubule growing in control and Aurora 
A-inhibited WT and KO cells. WT and KO cells were transfected with EB3-GFP, pre-
treated with MLN8237 or vehicle and allowed to settle on stimulatory anti-CD3/CD28-
coated surfaces and recorded under a confocal microscope. Fluorescence and bright field 
images for XYZ-stacks were taken every 1.2 s. MLN8237 or vehicle was present in the 
imaging medium. Movie was mounted at 10 fps. 
 
- Supplementary Movie 3. Tracking of EB3-GFP-decorated, growing TIPs at the IS 
in control Jurkat cells. Control Jurkat T cells stably expressing EB3-GFP were allowed 
to settle on stimulatory anti-CD3/CD28-coated surfaces and recorded under a TIRFm, at 
a 150 nm of penetrance upon excitation with a 488 nm laser. Images were taken every 
300 ms. MLN8237 or vehicle was present in the imaging medium. Imaris Software was 
used to recognize fluorescence corresponding to the decorated tips and to calculate the 
trajectories and growing speed of the tips. Movie was mounted at 30 fps.   
 
- Supplementary Movie 4. Tracking of EB3-GFP-decorated, growing TIPs at the IS 
in Aurora A-inhibited Jurkat cells. MLN8237-treated Jurkat T cells stably expressing 
EB3-GFP were allowed to settle on stimulatory anti-CD3/CD28-coated surfaces and 
recorded under a TIRFm, at a 150 nm of penetrance upon excitation with a 488 nm laser. 
Images were taken every 300 ms. MLN8237 or vehicle was present in the imaging 
medium. Imaris Software was used to recognize fluorescence corresponding to the 
decorated tips and to calculate the trajectories and growing speed of the tips. Movie was 
mounted at 30 fps.   
 
- Supplementary Movie 5. Tracking of EB3-GFP-decorated, growing TIPs at the IS 
in control CD4+ T cells. CD4+ T cells isolated from Aurka(lox/lox); RERT(ert/ert) and 
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transfected with EB3-GFP were allowed to settle on stimulatory anti-CD3/CD28-coated 
surfaces and recorded under a TIRFm, at a 150 nm of penetrance upon excitation with a 
488 nm laser. Images were taken every 300 ms. MLN8237 or vehicle was present in the 
imaging medium. Imaris Software was used to recognize fluorescence corresponding to 
the decorated tips and to calculate the trajectories and growing speed of the tips. Movie 
was mounted at 30 fps.    
 
- Supplementary Movie 6. Tracking of EB3-GFP-decorated, growing TIPs at the IS 
in Aurora A-deficient CD4+ T cells.  CD4+ T cells isolated from Aurka(lox/lox); 
RERT(ert/ert) treated with tamoxifen and transfected with EB3-GFP were allowed to 
settle on stimulatory anti-CD3/CD28-coated surfaces and recorded under a TIRFm, at a 
150 nm of penetrance upon excitation with a 488 nm laser. Images were taken every 300 
ms. MLN8237 or vehicle was present in the imaging medium. Imaris Software was used 
to recognize fluorescence corresponding to the decorated tips and to calculate the 
trajectories and growing speed of the tips. Movie was mounted at 30 fps.   
 
- Supplementary Movie 7. Tracking of CD3ξ-bearing vesicles at the IS in control 
Jurkat cells. Control Jurkat T cells transfected with CD3ξ-mCherry were allowed to 
settle on stimulatory anti-CD3/CD28-coated surfaces and recorded under a TIRFm, at a 
200 nm of penetrance upon excitation with a 561 nm laser. Images were taken every 100 
ms. MLN8237 or vehicle was present in the imaging medium. Imaris Software was used 
to recognize fluorescence corresponding to the vesicles and to calculate the trajectories, 
their duration and the speed of the vesicles. Movie was mounted at 20 fps.    
 
- Supplementary Movie 8. Tracking of CD3ξ-bearing vesicles at the IS in Aurora A-
inhibited Jurkat cells. MLN8237-treated Jurkat T cells transfected with CD3ξ-mCherry 
were allowed to settle on stimulatory anti-CD3/CD28-coated surfaces and recorded 
under a TIRFm, at a 200 nm of penetrance upon excitation with a 561 nm laser. Images 
were taken every 100 ms. MLN8237 or vehicle was present in the imaging medium. 
Imaris Software was used to recognize fluorescence corresponding to the vesicles and to 
calculate the trajectories, their duration and the speed of the vesicles. Movie was 
mounted at 20 fps.     
 
- Supplementary Movie 9. Tracking of CD3ξ-bearing vesicles at the IS in control or 
Aurora A inhibited CD4+ T cells. CD4+ T cells isolated from Aurka(lox/lox); 
RERT(ert/ert), transfected with EB3-GFP and CD3ξ-mCherry, treated with MLN8237 
or vehicle and  allowed to settle on stimulatory anti-CD3/CD28-coated surfaces. 
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Recording was performed under a TIRFm, at a 200 nm of penetrance upon excitation 
with a 561 nm laser. Images were taken every 110 ms. MLN8237 or vehicle was present 
in the imaging medium. Movie was mounted at 20 fps.    
 
- Supplementary Movie 10. 4D imaging of Actin ring formation in conjugates of in 
control and Aurora A-inhibited Jurkat cells. Control Jurkat T cells transfected with 
mCherry-β-actin were pre-treated with MLN8237 or vehicle, allowed to settle on 
stimulatory anti-CD3/CD28-coated surfaces and recorded under a confocal microscope. 
Fluorescence and bright field images for XYZ-stacks were taken every 25 s. MLN8237 
or vehicle was present in the imaging medium. Bar, 10 µm. Movie was mounted at 10 
fps.
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Aurora A is a serine/threonine kinase that contributes to the progression of mitosis by
inducing microtubule nucleation. Here we have identiﬁed an unexpected role for Aurora A
kinase in antigen-driven T-cell activation. We ﬁnd that Aurora A is phosphorylated at the
immunological synapse (IS) during TCR-driven cell contact. Inhibition of Aurora A with
pharmacological agents or genetic deletion in human or mouse T cells severely disrupts the
dynamics of microtubules and CD3z-bearing vesicles at the IS. The absence of Aurora A
activity also impairs the activation of early signalling molecules downstream of the TCR and
the expression of IL-2, CD25 and CD69. Aurora A inhibition causes delocalized clustering of
Lck at the IS and decreases phosphorylation levels of tyrosine kinase Lck, thus indicating
Aurora A is required for maintaining Lck active. These ﬁndings implicate Aurora A in the
propagation of the TCR activation signal.
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T
-cell activation depends on the ability of the T-cell receptor
(TCR) to recognize speciﬁc antigen peptides presented
in the context of the major histocompatibility complex
(MHCp) on the antigen-presenting cell (APC)1. The binding of
the TCR to MHCp promotes the formation of the immune
synapse (IS). In this process, the TCR and its associated
molecules localize to a central area of the T cell–APC contact,
the central supramolecular activating complex (cSMAC).
Adhesion molecules relocate to the peripheral SMAC2–4.
Essential proteins in this process are the Src family kinase
members (Lck and Fyn). Lck phosphorylates the immunoreceptor
tyrosine-based activation (ITAM) motifs of the TCR/CD3
complex5, leading to the recruitment of crucial molecules for
the downstream signalling pathways and the IS formation3.
The formation of the IS also triggers changes in the tubulin
cytoskeleton, including the translocation of the centrosome,
or microtubule (MT)-organizing centre (MTOC), to the IS,
accompanied by the Golgi apparatus, multivesicular bodies and
mitochondria6–8. These changes facilitate the polarized secretion
of cytokines and exosomes towards the APC9–11. MTOC
polarization orchestrates active MT growth and forms the core
of a dense MT network that regulates vesicular trafﬁc at the IS12.
The Aurora family of serine/threonine kinases comprises three
members in humans—Auroras A, B and C—which are encoded
by three different genes13 and are key regulators of different
mitotic processes14. Aurora A plays a critical role in centrosome
and spindle dynamics during mitosis, whereas Aurora B regulates
the attachment of the kinetochore to MTs and cytokinesis15.
Aurora A expression and activity peak in late G2 and the
protein is concentrated at centrosomes13,16. During centrosome
maturation, Aurora A promotes MT assembly by recruiting
nucleation and stabilization factors17. Aurora A is self-activated
by autophosphorylation at T288 in its T loop, helped by cofactors
including Bora, Tpx2, Ajuba and PAK1 (refs 14,18,19).
Owing to its role in controlling MT dynamics, we hypothesize
that Aurora A may play a role in the activation of T lymphocytes
during IS formation. Consistent with our hypothesis, we report
here that Aurora A is activated on TCR stimulation and controls
the dynamics of MT and CD3z vesicles at the IS. We have also
found an unexpected contribution of Aurora A to the early and
late signalling events in T cells. Speciﬁc targeting of Aurora A
impairs activation of the TCR/CD3 complex, by deregulating
Lck phosphorylation and location, preventing early T-cell
activation and downstream expression of CD69, CD25 and
interleukin (IL)-2. Our data reveal a novel role for Aurora A as a
major regulator of early signalling and the tubulin cytoskeleton
during T-cell activation.
Results
Active Aurora A localizes to the IS. To assess the speciﬁc
location of activated Aurora A, we conjugated human CD4þ
T cells from peripheral blood from healthy donors with beads
coated with stimulatory anti-CD3 and anti-CD28 antibodies,
and stained with anti-phospho-speciﬁc antibody against the
Aurora-T288 residue, which detects active Aurora A. In these
experiments, T288-phosphorylated endogenous Aurora A was
found in two different pools: one in the centrosome and the other
at the T-cell-bead contact region (examples of conjugates at
different stages of the process are shown; Fig. 1a); the low signal
of activated Aurora A in non-stimulated control conjugates
was not detected at the IS (Fig. 1a). Pretreatment of peripheral-
blood-derived human CD4þ T cells with the speciﬁc
Aurora A inhibitor MLN8237 blocked the phosphorylation of
Aurora A (Fig. 1a). Quantitative analyses showed that
phosphorylated Aurora A is accumulated at the IS in stimulated
CD4þ T cells, and that this is prevented by MLN8237 treatment
(Fig. 1b). Staining of phosphorylated endogenous Aurora A on
TCR stimulation was also abolished in T cells silenced
with speciﬁc small interfering RNAs (siRNAs) for Aurora A,
conﬁrming the speciﬁc binding of the antibody (Supplementary
Fig. 1a). Active Aurora A also localized at the IS in conjugates
of naive mouse OTII T lymphocytes with primary dendritic
cells pulsed with OVA peptide (Fig. 1c). These results clearly
show that TCR triggering promotes the activation of Aurora A
and its recruitment to the IS. However, pretreatment of J77 cells
with the speciﬁc Aurora A inhibitor MLN8237 did not alter the
number of conjugates formed with staphylococcal enterotoxin E
(SEE)-pulsed Raji cells (Supplementary Fig. 1b), indicating that
inhibition of Aurora A does not result in a global defect in
cytoskeleton dynamics.
To parse the localization of activated Aurora A with respect to
total Aurora A, we transfected primary CD4þ T cells with
Aurora A-GFP wild type (WT) or Aurora A-GFP KD
(kinase dead mutant) and then conjugated the transfected cells
with stimulatory anti-CD3/CD28-coated beads (Fig. 1d,e).
Quantitative analysis of Aurora A-GFP or active Aurora A
(Aurora A T288) accumulation demonstrated that it is mainly
found at the IS. However, Aurora A KD accumulation at the
IS is signiﬁcantly decreased, compared with WT. Moreover,
overexpression of the Aurora A-GFP KD mutant, disperses the
remaining active protein. Thus, the phosphorylated active form of
Aurora A is speciﬁcally recruited to the IS.
Aurora A controls MT dynamics at the IS. Aurora A plays an
important role in the dynamics of the centrosome during
mitosis20,21. To ascertain its possible function in MT dynamics
and centrosomal polarity during T-cell activation, we analysed
the dynamics of the microtubular network in CH7C17 T cells
transiently transfected or stably expressing an EB3-GFP fusion
protein (EB3 cells; Fig. 2a–d and Supplementary Movie 1). EB3
and EB1 (end-binding proteins) are plus-tip-tracking proteins
that are also found in the pericentrosomal matrix and promote
MT growth22. Cells were settled on anti-CD3/CD28-coated
chambers and time-lapse confocal three-dimensional (3D)
imaging was performed by XYZ stack acquisition. The
stimulating surface allows IS-like formation, associated
centrosome polarization and MT polymerization12. EB3 cells
were pretreated or not (vehicle) with MLN8237 for 30min before
imaging. Maximal projection of the XYZ stack (Fig. 2a and
Supplementary Movie 1) revealed that the relative amount of
EB3-GFP incorporated into MT plus ends (þ tips) was clearly
decreased in Aurora A-inhibited cells. This effect was measured
in 3D as the ratio of EB3-GFP ﬂuorescence incorporated in
þ tips with respect to the whole-cell ﬂuorescence using Imaris
software, conﬁrming that Aurora A-inhibited cells polymerize
MTs less efﬁciently (Fig. 2b and Supplementary Movie 1). The
amount of polymerized MT observed along the time course was
clearly decreased in MLN8237-treated cells (Fig. 2a). We also
analysed the localization of the MTOC and the EB3-GFP
ﬂuorescence by 3D and orthogonal projections of the XYZ
stacks. Fluorescence was mainly detected close to the stimulating
surface (Fig. 2c,d). This can be also observed by comparing
bottom and top slices of the XYZ stacks (Supplementary Fig. 2a).
Despite the effect of Aurora A inhibition on MT dynamics, no
signiﬁcant change on MTOC translocation in cell conjugates was
observed either at 10 or at 30min of activation (Fig. 2e).
To further assess the function of Aurora A in primary naive
T cells, we used a mouse model of conditional Aurora deﬁciency.
CD4þ cells were isolated from lymph nodes and spleens of
experimental [Aurka(lox/lox); RERT(ert/ert)] (knockout (KO)
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mice) and control [Aurka(þ /þ ); RERT(ert/ert)] (WT mice),
treated with tamoxifen and IL-7 for 96 h, to suppress Aurora A
expression (Fig. 3a). These cells were transfected with a plasmid
encoding EB3-GFP and then activated with anti-CD3/CD28
stimulating monoclonal antibodies (Fig. 3b,c and Supplementary
Movie 2). We found that Aurora A-deﬁcient T cells had
signiﬁcantly less EB3 incorporation in MT þ tips than their
WT counterparts (Fig. 3b,c and Supplementary Movie 2).
Furthermore, the effect of Aurora A deﬁciency was similar to
the effect of the MLN8237 inhibitor on WT cells, whereas the
inhibitor did not have additional effects on Aurora A KO cells,
suggesting that these and previously recorded effects of the
inhibitor were Aurora A speciﬁc. MTOC and EB3-GFP
tracking of MTs was also observed at the bottom of the cells
(Supplementary Fig. 2b,c).
We next tracked the dynamics of MT growth using EB3-GFP
imaging and total internal reﬂection ﬂuorescence (TIRF)
microscopy in cells settled on anti-CD3/CD28-coated surfaces,
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Figure 1 | Aurora A is located at the IS contact area and is activated on TCR triggering. (a) Maximum Z projection of a confocal stack of human primary
CD4þ T cells pretreated with vehicle (DMSO) or Aurora A inhibitor (MLN8237, 10mM) and conjugated with anti CD3/CD28-coated beads. Images show
three representative conjugates in DMSO and two in MLN8237-treated cells at different stages of cell conjugation. Cells were ﬁxed and stained for PKCy
(red), T288-phosphorylated Aurora A (magenta) and a-tubulin–ﬂuorescein isothiocyanate (FITC) (green). Bright ﬁeld with DAPI frames are included. Scale
bar, 10mm. (b) Quantiﬁcation of T288-phosphorylated Aurora A accumulation at the IS contact area in conjugates as in a from three independent experiments
(n¼ 93 in non-activated, n¼ 105 in DMSO, n¼ 109 in MLN8237). Data represent means±s.d. Means were compared with a t-test. (c) Maximum Z
projections of confocal stacks of transgenic OTII CD4þ cells conjugated with OVA peptide-pulsed bone-marrow-derived dendritic cells (DCs). Cells were
incubated for 30min, ﬁxed and immunostained for T288-phosphorylated Aurora A (magenta) and actin (green). The right-hand image shows CMAC cell
tracker labelling of DCs (cyan) and bright ﬁeld. Scale bar, 10mm. (d) Maximum Z projection of a confocal stack of human primary CD4þ Tcells transfected
with Aurora A-GFP WTor Aurora A-GFP KD (green) and conjugated with anti CD3/CD28-coated beads. Cells were incubated for 30min, ﬁxed and stained
for T288-phosphorylated Aurora A (magenta). Bright ﬁeld with DAPI frames are included. Scale bar, 10mm. (e) Quantiﬁcation of T288-phosphorylated Aurora
A and transfected Aurora A accumulation at the IS contact area in conjugates as in d (n¼45 in Aurora A-GFP WT, n¼ 29 in Aurora A-GFP KD).
Data represent means±s.d. Means were compared with a t-test. n.s., nonsigniﬁcant. *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001.
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to improve the XY spatial and time resolution23–25. EB3 cells were
treated with MLN8237 or dimethyl sulfoxide (DMSO; vehicle) for
30min before imaging and images were taken every 300ms.
MLN8237-treated EB3-GFP cells had fewer EB3-decorated tips
emerging from the centrosome, indicating impaired MT growth
(Fig. 3d,e and Supplementary Movies 3 and 4). MT growth
was similarly impaired in Aurora-KO primary CD4þ T cells,
displaying fewer and slower growing MTs than control
cells (0.140±0.037 and 0.190±0.023 mms 1, respectively;
mean±s.d.) (Fig. 3f,g and Supplementary Movies 5 and 6).
Thus, these results show that the MT network at the IS is
disrupted in T cells with defective Aurora A activation.
Aurora A regulates CD3f-bearing vesicles trafﬁc at the IS. The
impaired MT growth observed in Aurora A-targeted T cells did
not affect the localization of the surface TCR/CD3 complexes at
the IS, as TCR/CD3e was comparably clustered at the IS of
untreated and MLN8237-treated T-cell conjugates with APC
(Fig. 4a,b). We next assessed the dynamics of CD3z-bearing
vesicles at the IS. CD3z trafﬁcs through endosomal compartments
towards the IS26. These vesicles move associated to MTs and
support the sustained activation of the T cell at the IS12,27. The
vesicles enter and leave the TIRF plane, some of them moving
towards the position of the centrosome at the centre of the IS-like
structure, probably along the MTs. Jurkat T cells expressing
CD3z-mCherry were treated with DMSO or MLN8237, settled
onto anti-CD3/CD28 and analysed by TIRF microscopy. Images
were taken every 100ms (200 nm penetrance) and the trajectories
of detected vesicles were tracked. Treatment with MLN8237
decreased the number of vesicles at the IS-like structure and
disrupted the movement of those that were present (Fig. 4c,d and
Supplementary Movies 7 and 8). Therefore, the effect of Aurora A
inhibition on MT dynamics impedes the movement of
vesicles towards the IS structure, a ﬁnding conﬁrmed by the
reduced speed of vesicles in Aurora A-inhibited cells (Fig. 4d).
A similar phenotype was observed in Aurora KO cells, with
few or no vesicles moving towards the centre of the IS-like
structure. Treatment of WT cells with the Aurora A inhibitor
caused a similar effect to Aurora A-deﬁciency (Fig. 4e,f and
Supplementary Movie 9).
Aurora A blockade does not affect TCR-driven actin dynamics.
To further analyse the role of Aurora A in the control of
cytoskeletal dynamics at the IS, we assessed the effect of Aurora A
inhibition on the activation-dependent interaction of TCR/CD3
with the actin–cytoskeleton-associated protein Nck. This
interaction is enabled by the conformational change in the
TCR/CD3e complex on antigenic triggering28. Aurora A
inhibition had no effect on CD3z–Nck association in pull-down
assays (Fig. 5a). This is in agreement with a surface recruitment
and accumulation of TCR/CD3e to the IS in Aurora A-inhibited
cells (Fig. 4a,b). Using a similar approach, we assessed whether
Aurora A impairment affects the activation of the small GTPase
Rac1, a hallmark for TCR-dependent actin polymerization29.
Likewise, no effect was detected in Rac1 pull-down assays
with the GST-PAK-CD (p21-activated kinase CRIB Domain30)
in stimulated CD4þ T cells when using MLN8327 inhibitor
(Fig. 5b). Furthermore, the Aurora A inhibitor did not affect
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Figure 2 | MT dynamics at the IS is impaired by Aurora A chemical inhibition. (a–d) Imaging of EB3-GFP-expressing CH7C17 T cells (pretreated with
DMSO or MLN8237 and settled on corresponding anti-CD3/CD28-coated glass-bottom chambers). Maximal projection of XYZ stacks for ﬂuorescence
and single bright-ﬁeld (BF) images are shown. Scale bar, 10mm. (b) Ratio of EB3-GFP ﬂuorescence incorporated in þ tips from XYZ stacks (0 s; n¼ 34 in
DMSO and n¼43 in MLN8237). Data represent means±s.d. Means were compared with a Mann–Whitney test. (c) Orthogonal and 3D projections from
XYZ stacks. Dotted white or red lines indicate contact with substrate or media, respectively. (d) Ratio of the MTOC location from the IS-like structure
(n¼ 38 in DMSO, n¼44 in MLN8237). (e) Distance from the T-cell MTOC to the APC contact area in conjugates of T cells with SEE-pulsed APCs
(10min, n¼ 166 in DMSO, n¼ 168 in MLN8237; 30min, n¼412 in DMSO, n¼ 394 in MLN8237). Data represent means±s.d. from three independent
experiments. Means were compared with a t-test.
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the spreading of mCherry–b-actin-expressing T cells on
anti-CD3/CD28-coated coverslips, measured either as the total
occupied surface or as the rate of membrane extension on the
coverslip (Fig. 5c,d). This ﬁnding correlated with a similar
distribution of mCherry–b-actin at the peripheral SMAC and
cSMAC in control and Aurora A-inhibited cells. Aurora A
inhibition also had no effect on the total area occupied by adhered
cells or their lamellae (Fig. 5d). Similarly, actin accumulation at
the IS in T cell–APC conjugates was not signiﬁcantly affected
by inhibition of Aurora A (Fig. 5e,f). We therefore analysed
the formation of the actin ring in cell conjugates using time-lapse
3D confocal imaging. Actin accumulation and ring formation was
similar in control and MLN8237-treated cells (Fig, 5g,h and
Supplementary Movie 10). Therefore, Aurora A appears to
speciﬁcally affect the tubulin cytoskeleton at the IS, without
affecting actin-based dynamics.
Aurora A inhibition impairs early TCR signalling. To assess the
possible role of Aurora A in TCR signalling, we analysed the
phosphorylation of several canonical downstream molecules that
are phosphorylated in response to cognate interactions in
SEE-stimulated Jurkat T cells (Fig. 6a,b) and anti-CD3/CD28-sti-
mulated human primary CD4þ T cells (Fig. 6c,d). The
phosphorylation of speciﬁc residues in CD3z (Y83), LAT (Linker
for Activation of T cell; Y132), PLCg1 (Phospholipase C; Y783),
PKCy (T538) and ERK1/2 (T202/Y204) was greatly diminished on
Aurora A inhibition with MLN8237. The role of Aurora A in TCR
signalling was also conﬁrmed in an MHC/peptide-speciﬁc system,
in which MLN8237-treated CH7C17 Jurkat T cells were stimulated
with Hom2 lymphoblastoid B cells preloaded with haemagglutinin
(HA) peptide (Fig. 7a,b). The effect of Aurora A inhibition on TCR
downstream signalling was dose dependent (Supplementary
Fig. 3a,b). As a control of MLN8237 speciﬁcity, we added the
inhibitor just before the activation of T cells and the same effect
was observed (Supplementary Fig. 3c). By extensively washing the
inhibitor before activation, the phosphorylation levels of these
speciﬁc residues were restored, indicating that the effects of the
inhibitor were reversible (Supplementary Fig. 3d). MLN8237
shows a 200-fold higher selectivity for Aurora A over Aurora B31;
nonetheless, to rule out a possible role of Aurora B, we treated J77
T cells with AZD1152 (100nM), which is 3,700 times more
selective for Aurora B32. AZD1152 had no effect on the
phosphorylation of T-cell proteins (Supplementary Fig. 4),
conﬁrming that proper T-cell activation critically depends of the
isoform A, but not B, of Aurora kinase. This was further conﬁrmed
in conjugates of Aurora-A-silenced Jurkat T cells and
Staphylococcal enterotoxin B (SEB)-preloaded Hom2 B cells as
b
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Figure 3 | Aurora A gene ablation impairs MTdynamics at the IS. (a) Immunoblot analysis of Aurora A protein expression in CD4þ Tcells WTand KO.
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MLN823). Data represent means±s.d. Means were compared with a Mann–Whitney test. Map of the trajectories of EB3-GFP-decorated MT plus tips in
human CH7C17 Tcells pretreated with DMSO or MLN8237 (d,e), or in Aurora-A-deﬁcient and control CD4þ Tcells (f,g) and settled on anti-CD3/CD28-
coated glass-bottom chambers. Images were taken every 300ms under a TIRF microscope at a penetrance of 150 nm. MT þ tips were tracked with Imaris
software over 5 (d) or 2min (f). Maximal projections of the time lapse from representative cells are shown. Scale bar, 10mm. (e,g) Quantiﬁcation of the
number of MTplus tip tracks presented in d (e; n¼ 7 in DMSO, n¼9 in MLN8237) and g (f; n¼ 6). Error bars represent interquartile rage. Medians were
compared with a Mann–Whitney test. n.s., nonsigniﬁcant. *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001.
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APCs. The activation of CD3z-dependent molecules was
defective in Aurora-A-silenced cells, with below-normal LAT
phosphorylation on residue Y132, probably responsible for the
concomitant decreases in PLCg1 (Y783) and PKCy (T538)
phosphorylation (Supplementary Fig. 5a).
To determine the role of Aurora A in late events of T-cell
activation, we examined the messenger RNA expression of IL-2,
CD25 and CD69. Human CD4þ T lymphocytes were treated
with MLN8237 and AZD1152 or vehicle for 30min, and
stimulated with anti-CD3/CD28 antibodies for 3 h. Inhibition of
Aurora A impaired the upregulation of IL-2, CD25 and CD69
mRNA determined by reverse transcriptase–PCR (Fig. 7c),
indicating a defect in late T-cell activation. In contrast, Aurora
B inhibition had no effect on the mRNA production of these
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genes, supporting a speciﬁc role for Aurora A and its regulated
pathways in T-cell activation.
TCR signalling is impaired in Aurora-A-deﬁcient mice. Phar-
macologic inhibition of Aurora A also impaired early T-cell
activation in mouse naive CD4þ T cells polyclonally stimulated
with anti-CD3/CD28 (Fig. 8a). To further assess the function of
Aurora A in primary naive T cells, we deleted Aurora A
expression in CD4þ cells from the conditional Aurora KO
mice and activated them with anti-CD3/CD28 antibodies.
Tamoxifen-induced suppression of Aurora A expression in
Aurka(lox/lox); RERT(ert/ert) cells (Fig. 3a) correlated with clear
decreases in the phosphorylation of CD3z (Y83), LAT (Y132),
PLCg1 (Y783), PKCy (T538) and ERK1/2 (T202/Y204)
(Fig. 8b,c). CD4þ T cells from the conditional Aurora KO mice
were also treated with MLN8237, obtaining a slight decrease in
the phosphorylation of PLCg1 (Y783) when compared with
vehicle-treated CD4þ T cells from the conditional Aurora KO
mice (Supplementary Fig. 5b). In complementary experiments,
we examined a transgenic mouse model of Aurora A
overexpression33. Naive CD4þ T cells isolated from lymph nodes
and spleens of Col1a1tetO-Aurka/þ ; Rosa26rtTA/rtTA mice
(Aurora KI) and controls were treated with doxycycline and IL-7
for 24 h, followed by activation with anti-CD3/CD28 antibodies.
Doxycycline treatment increased Aurora A expression in the
conditionally transgenic cells (Fig. 8d), correlating with increased
levels of TCR-dependent signalling (Fig. 8e,f).
Aurora A controls Lck kinase location and phosphorylation. To
study the mechanism underlying the earliest T-cell activation
defects in the absence of Aurora A, we assessed the possible
regulation of the Src kinase Lck by Aurora A. Lck phosphorylates
CD3 ITAMs at tyrosine residues on TCR triggering and shows
autophosphorylation activity towards its Y394 residue, an
activatory residue34. By quantitative analysis of Lck accumulation
at the IS we have detected a signiﬁcant reduction in Lck
relocation to the IS contact area, as a result of Aurora A inhibition
in Jurkat T cells (Fig. 9a,b). In accordance with a perturbed Lck
localization, pharmacologic inhibition of Aurora A in human
primary CD4þ T cells impaired Lck autophosphorylation at
Y394, a hallmark of its catalytic activity (Fig. 9c,d). Notably, these
experiments showed that Lck-Y394 phosphorylation was
impaired before TCR stimulation, suggesting a role of Aurora A
in the maintenance of the preactivated pool of Lck34.
To analyse whether the effect of Aurora A on Lck activation is
dependent on the intracellular trafﬁc of Lck27 and taking into
account that Lck recruitment at the IS is also driven by its
association with CD4 (ref. 35), we decided to assess T-cell
activation in a Lck-deﬁcient cell line (J.CAM1 (refs 36,37))
reconstituted with full-length Lck-GFP or murine CD4-Lck
chimeric proteins. CD4-Lck is mainly localized at the
plasma membrane38,39. A murine CD4 lacking its cytosolic tail
and fused to GFP was used as a negative control40 (Fig. 9e;
CD4-DCyt-GFP). We found that Lck-GFP expression rescued
CD3 phosphorylation and thus T-cell activation in J.CAM1,
whereas MLN8237 treatment prevented such an effect. Rescue of
J.CAM1 signalling with CD4-Lck chimera was also prevented
with the Aurora A inhibitor. Therefore, Aurora A activity is
needed for Lck activity independently of its intracellular
trafﬁcking during IS formation.
Immunoprecipitation (IP) of Lck followed by mass
spectrometry (MS) analysis revealed that Aurora A inhibition
resulted in a decrease of Lck phosphorylation at the activation
residue Y394 in resting and stimulatory conditions (Fig. 9f). This
was further corroborated by in vitro kinase assays of puriﬁed
recombinant Lck protein by immunoprecipitated Aurora A
proteins. Although WT Aurora A protein keeps Lck phos-
phorylated at residue Y394, a KD form of Aurora is unable to
maintain Lck phosphorylation at Y394 (Fig. 9g). Treatment with
the Aurora A inhibitor corroborated the KD results (Fig. 9g).
Together, these results highlight the relationship of Aurora
A-mediated signal spreading at the IS with Lck location,
phosphorylation and, therefore, regulation.
Discussion
In this study we have analysed the inﬂuence of a well-known cell
cycle regulator, Aurora A kinase, in T-cell activation. Our results
provide novel evidence that Aurora A is a key regulator of early
TCR-dependent signalling pathways and controls signalling
vesicle and microtubular dynamics. However, the direct
interaction of TCR/CD3 with Nck and actin polymerization at
IS are not affected by Aurora A inhibition. Aurora A localizes at
the IS and appears activated on antigen- and superantigen-driven
T-cell activation. Early activation of Aurora A seems to be
essential for TCR downstream signalling, leading to LAT and
PLC activation. In addition, our data provide mechanistic insight
into how Aurora A acts as master regulator of T-cell activation by
controlling Lck phosphorylation and clustering at the IS.
Aurora A localization to centrosomes and along spindle MTs at
the beginning of mitosis is well characterized13,17. The location of
Aurora A in interphase is not well established, although the
human protein atlas indicates that nuclear and cytoplasmic pools
co-exist (http://www.proteinatlas.org/). Our data reveal that a
fraction of active Aurora A (T288) appears at the IS contact area
and a second pool is concentrated at the pericentrosomal area.
The active form at the IS was observed on TCR stimulation,
whereas the centrosome fraction seemed to be basally active in
primary CD4þ T cells. The active pool and the total protein
showed a similar pattern, indicating that there is an active
redistribution of the protein on stimulation. This highlights the
possibility that Aurora A autophosphorylation might have a role
on its own localization at the IS, which is also supported by
the fact that the expression of an Aurora A KD mutant provokes
the delocalization of the active protein at the IS. However, further
studies should be conducted to prove this view. The presence of
two detectable pools suggest that Aurora A may play a possible
dual role in controlling MT dynamics and T-cell activation.
Although Aurora A can autophosphorylate, it is conceivable that
other kinases are also involved in its activation. The
MT-associated protein Tpx2 can activate Aurora A through its
stabilization during cell division and prevents PP1 phosphatase
from inactivating Aurora A41. Therefore, the distribution of
activated Aurora A at the IS, a zone where a complex
microtubular network is rapidly organized, may be responsible
for its stabilization and activation, establishing a positive feedback
for tubulin dynamics.
Aurora A contributes to centrosome maturation through the
recruitment of MT nucleation factors. However, its absence does
not prevent the formation of the centrosomal MT aster but
instead affects the density of the aster formed in other systems17.
Our TIRF microscopy analysis demonstrates that Aurora A
controls growing MT arising from the MTOC on TCR activation,
while having no apparent effect on MTOC translocation at the IS.
In addition, during the M phase Aurora A is required for the
recruitment of adaptor proteins such as NEDD1 for the correct
formation of the mitotic spindle42. Previous work on proteins
implicated in MT regulation such as EB1 or HDAC6 (refs 12,43)
showed a defect in late T-cell activation. The role of these proteins
in MT cytoskeleton dynamics and T-cell activation seemed to be
mainly related to the maintenance of the TCR signal rather than
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its initial activation. Aurora A might regulate late T-cell activation
through a similar mechanism. Our data indicate that the decrease
in the number of MTs nucleated near the contact area may affect
polarized secretion from this area and vesicular trafﬁcking at the
IS and throughout the T cell. Hence, Aurora A inhibition
prevents movement of CD3z vesicles around the MTOC almost
completely, possibly reﬂecting a global effect on vesicle
trafﬁcking. In addition, as CD3 is tightly regulated by its cycle
of degradation and recycling44, the absence of this pool of CD3z
vesicles at the cSMAC may explain why the TCR signal cascade is
not properly propagated. It has been proved that there is a pool of
phosphorylated CD3z that, instead of going to a degradation
pathway, keeps accumulated at the endosomal compartment,
ready to maintain CD3z phosphorylation signalling26. Although
Aurora A inhibition has no effect in TCR/CD3e subunit surface
clustering at the IS, the transport of vesicles of the CD3z subunit
is clearly impaired. Taking into account the presence of this
phosphorylated CD3z pool at the endosomal compartment,
Aurora A might have an effect mainly over this recycling of the
active CD3z and, therefore, over TCR signal propagation.
Although Aurora A contributes to actin cytoskeleton dynamics
in mitosis and during mammary cell migration, no such effect
was observed during IS formation by spreading T cells.
Aurora-A-mediated phosphorylation of LIM kinase 1 at the
centrosomes in prophase is essential for modulation of actin
ﬁlaments and subsequent spindle formation. LIM kinase 1 acts by
inactivating the phosphorylation of the actin depolymerizing
family protein coﬁlin, thus stabilizing the cortical actin network
during spindle orientation45. In mammary cell migration, Aurora
A promotes increased expression of the coﬁlin phosphatase SSH1,
resulting in coﬁlin activation and actin reorganization and
migration46. However, our data show that Aurora A inhibition
affects neither actin accumulation during IS formation nor cell
spreading. Indeed, we found that Aurora-A-inhibited T cells form
normal-shaped lamellae. During IS formation, Nck acts as a
bridge between the TCR activation and actin cytoskeleton
reorganization at the IS. When the TCR recognizes a speciﬁc
antigen, a conformational change in the CD3e chain unmasks a
neoepitope to which Nck binds, leading to transmission of the
activation signal through the actin cytoskeleton28. CD3e-NcK
association is not affected by Aurora A inhibition, a ﬁnding in
accordance with the absence of changes in actin accumulation at
the IS in MLN8237-pretreated T cells.
Our results show regulatory effects of Aurora A on early and
late T-cell signalling. Inhibition of Aurora A abrogates proper
T-cell activation determined by the phosphorylation proﬁle of
TCR signalling proteins such as CD3, and the adapter proteins
and kinases LAT, PLCg1 and PKCy. These effects on TCR
pathway phosphorylation events were observed in response to the
Aurora A inhibitor MLN8237 and Aurora A gene ablation in
mouse T cells, indicating that this is a speciﬁc consequence of
Aurora A inhibition. The initial activation of T cells occurs at the
plasma membrane; however, its continued progress requires the
contribution of intracellular components such as the MTOC and
the MT-dependent vesicular trafﬁc and mitochondrial activity3.
Thus, Aurora A contributes to the propagation of TCR
activation to the intracellular compartment, leading to
activation of genes such as IL-2, CD69 and CD25. Moreover,
the strength of T-cell activation can determine the ability of
T cells to divide asymmetrically, thereby promoting functional
differentiation into subpopulations of T cells that regulate the
immune response47. Our data suggest that T lymphocytes
defective in Aurora A do not become properly activated,
possibly affecting the outcome of the adaptive immune response.
However, neither the defect on MT dynamics nor the
impairment in CD3z vesicle transport can explain the blockade
of the initial trigger of TCR signalling. These early defects of
CD3z-dependent signalling in Aurora A-targeted cells are more
likely to be explained by altered activity of Src kinases. This family
includes Lck and Fyn, the ﬁrst kinases to phosphorylate the
ITAMs in CD3, which are required for full activation and signal
transmission5,48. Our data demonstrate that Lck location and
phosphorylation are altered by chemical inhibition of Aurora A,
demonstrating that Aurora A controls TCR pathways dependent
on CD3-ITAM phosphorylation. Nevertheless, the interaction of
the kinase with the HSP90 and HSP70 chaperones is maintained
in the presence of MLN8237, indicating that the inhibitor does
not seem to affect its life time (Blas-Rus et al., unpublished data).
Previous work on Lck regulation has described the initial steps
on the activation of this protein. A ‘standby’ model has been
proposed, where there is a pool of preactivated Lck whose
phosphorylation does not change on TCR activation34. In this
context, Lck function could be regulated through conformational
changes, clustering and the spatio-temporal proximity to CD45
phosphatase, as well as with the exposition of the
phosphorylatable ITAMs on TCR engagement34,49,50. However,
other recent works detected a pool of Lck that became activated
on TCR triggering assessed either by FRET-FLIM techniques51 or
other different methods52. On the other hand, other studies
addressed the importance of Lck spatial distribution in speciﬁc
lipid rafts that rearrange on MHC–TCR binding49,53,54. In this
regard, our results by complementary experimental strategies
including western blot (WB) analysis of protein activation and
MS analysis of endogenous Lck, and of in vitro kinase assays with
Figure 5 | Aurora A inhibition does not affect actin cytoskeleton dynamics. (a) Immunoblot of a pull-down assay of GST-Nck fusion protein from cell
lysates of control (DMSO; vehicle) or Aurora A inhibitor (MLN8237)-pretreated human T lymphoblasts. Activation was performed with soluble anti-CD3e
antibodies for indicated times. CD3z and GST are shown. CD3z content in whole-cell lysates is indicated in the bottom row. (b) Immunoblotting of Rac1
pull-down assay of GSTand GST-PAK-CD from cell lysates of DMSO- or MLN8237-pretreated Jurkat T cells activated with SEE-pulsed Raji B cells (APCs)
for the indicated times. Loading control for Rac1 in whole-cell lysates is shown. (c) Images from TIRFm time-lapse analysis of mCherry–b-actin-expressing
Jurkat T cells spreading over anti-CD3/CD28-coated glass-bottom chambers. Cells were pretreated with DMSO or MLN8237. Images were taken every
100ms for 5min at 90 nm penetrance. A corresponding bright-ﬁeld image is shown. Scale bar, 10mm. (d) Quantiﬁcation of the area occupied by the whole
cell (lamella), the actin-rich area (peripheral SMAC (pSMAC)), the central area (cSMAC) and the distribution of mean ﬂuorescence intensity per area
(ratios cSMAC:cell; pSMAC:cell and cSMAC/pSMAC) from cells in c (n¼48 and n¼ 36, three independent experiments). Cells were ﬁxed after spreading
(4min) and ﬂuorescence images were taken. Data represent means±s.d.; t-test. n.s., nonsigniﬁcant. (e) Maximum Z projections of confocal stacks from
DMSO- or MLN8237-pretreated Jurkat T cells conjugated with SEE-APCs. Cells were incubated for 30min, ﬁxed and stained for a-tubulin (green) or actin
(magenta). The right-hand image shows CMAC cell tracker labelling of APCs (cyan) and bright ﬁeld. Scale bar, 10mm. (f) Quantiﬁcation of actin
accumulation at the IS contact area in conjugates as in e from three independent experiments (n¼ 100). Data represent means±s.d.; t-test.
(g) Image sequence for IS formation between mCherry–b-actin-expressing Tcells and SEB-APCs (DMSO- or MLN8237-treated). XYZ stacks were acquired
every 25 s (maximal projections of XYZ stacks and 3D reconstructions with Imaris Software are shown from representative conjugates). (h) Ratio of Tcells
forming lamella on contact with an APC from g. Data represent median±interquartile range. Mann–Whitney test (DMSO: 28 cells (n¼4); MLN8237: 25
cells (n¼ 3)).
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puriﬁed recombinant Lck protein indicate that the activating Lck
residue Y394 is phosphorylated in T cells before TCR stimulation.
Remarkably, the targeting of Aurora A decreases Y394
phosphorylation and shows a delocalized Lck clustering at the IS.
Reconstitution experiments in the Lck-deﬁcient cell line J.CAM1 by
either Lck-GFP or CD4-Lck, which retains Lck at the plasma
membrane, revealed that Aurora A is required for TCR signalling in
both situations. Taking into account the importance of Lck spatial
distribution and proper phosphorylation for its activity, the
dephosphorylation and mislocalization of Lck in the absence of
Aurora A activity may explain the observed defects in TCR
signalling pathways. A detailed analysis of other phosphorylated
residues, including Ser/Thr, is needed to understand the complex
regulation of Lck by Aurora A and this deserves future
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investigation. Furthermore, the assessment of how Aurora A
controls Lck activity, either directly or indirectly through associated
kinases, is an issue that remains to be explored.
In summary, our results show that Aurora A plays an
important role in the early events initiated on TCR stimulation
and unravel a novel molecular mechanism that regulates early
signalling and cytoskeletal and vesicle dynamics in T cells. The
prevention of T-cell activation by Aurora A inhibition has
important clinical implications. Aurora A inhibitors are currently
under evaluation for cancer therapy in Phase I–II clinical trials55.
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In these trials, aggressive B-cell and T-cell non-Hodgkin
lymphomas have shown an overall positive response, promoting
new Phase III studies. It will be important to deﬁne the extent to
which the new function reported here participates in these
responses and to determine whether the T-cell activation pathway
can provide new biomarkers, critical for understanding these
therapeutic effects. Very recently, a transcriptomic analysis points
Aurora A as a targetable molecule for graft versus host disease
prevention in a primate model56. Hence, our data provide a
mechanistic explanation by how Aurora A controls T-cell
activation. Given the importance of Aurora A inhibitors in
cancer therapy, these results may provide new opportunities for
treating lymphocyte diseases such as graft versus host disease,
T-cell lymphomas or leukaemias.
Methods
Cells. The human Jurkat-derived T-cell lines J77 (Val.2 Vb8þ TCR) and J.CAM1
(refs 36,37), the lymphoblastoid B-cell lines Raji (Burkitt lymphoma; acquired from
the DSMZ Organization; ACC-319) and Hom2 (HLA-DR1 EBV-transformed)
were cultured in RPMI 1640þGlutaMAX–Iþ 25mM HEPES (Gibco–Invitrogen)
supplemented with 10% fetal bovine serum (Hyclone, Thermoﬁsher). The human
Jurkat-derived CH7C17 cells (Vb3þ transgenic TCR, speciﬁc for HA peptide)
were grown in the same medium supplemented with 400 mgml 1 hygromycin B
(Roche Diagnostics) and 4 mgml 1 puromycin (Invitrogen, Eugene, OR, USA).
CH7C17 (ref. 57) clones expressing EB3-GFP were generated by CH7C17
transfection and post selection with G418 (1mgml 1). All lymphoid cell lines
were tested for speciﬁc expression of CD (clusters of differentiation) with speciﬁc
antibodies by ﬂow cytometry. HEK293T cells were cultured in DMEM medium
(Invitrogen) supplemented with 10% fetal bovine serum, 50 IUml 1 penicillin and
50 mgml 1 streptomycin, and exclusively used to produce and purify recombinant
proteins. All cell lines were routinely tested for mycoplasm. Human peripheral
blood mononuclear cells (PBMCs) were isolated from buffy coats obtained from
healthy donors by separation on a Biocoll gradient (Biochrom) according to
standard procedures. Monocytes were separated from PBMCs by a 30-min
adherence step at 37 C in RPMI supplemented with 10% FCS. Non-adherent cells
were washed off and CD4þ T cells were puriﬁed from PBMCs using magnetic-
activated cell sorting (MACS; Miltenyi Biotech). Non-adherent cells were obtained
after 30min of the adhesion step at 37 C. To generate SEE-responsive human T
lymphoblasts, PBMCs were cultured for 5 days in the presence of SEE
(0.1 mgml 1) and then phytohaemagglutinin (5 mgml 1) was added for 2 days.
To favour its proliferation, IL-2 (50Uml 1) was added later to the medium every
2 days for a time period of 8 days. These studies were performed according to the
principles of the Declaration of Helsinki and approved by the local Ethics
Committee for Basic Research at the Hospital La Princesa (Madrid); informed
consent was obtained from all human volunteers. These studies were performed
according to the principles of the Declaration of Helsinki and approved by the local
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Figure 7 | Aurora A inhibition impairs TCR signalling and gene expression. (a) Immunoblottings showing phosphorylation of the molecules indicated
in lysates of CH7C17 Jurkat T cells pretreated with DMSO or MLN8237 and conjugated for the indicated times with HA-peptide-pulsed Hom2 B cells.
(b) Quantiﬁcation of blots as in a–c from four to six independent experiments. Error bars represent interquartile range. Medians were compared with a
Friedman test (*Po0.05). n.s., nonsigniﬁcant. (c) IL2, CD69 and CD25 mRNA levels in primary human CD4þ T cells pretreated with DMSO, MLN8237
(10mM) or the Aurora B inhibitor AZD1152 (100 nM) and activated by settling on anti-CD3/CD28-coated plates for 4 h. mRNA levels were normalized to
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Ethics Committee for Basic Research at the Hospital La Princesa (Madrid);
informed consent was obtained from all human volunteers.
Mice. The Aurora A conditional model has been described58. These
mice carry an Aurka(lox) conditional allele and the RERTert allele expressing
an inducible Cre recombinase. After the appropriate crosses, we obtained the
experimental Aurka(lox/lox); RERT(ert/ert) and control Aurka(þ /þ );
RERT(ert/ert) mice used in this study. Cre activation on tamoxifen treatment
induces conversion of the Aurka(lox) allele to the Aurka(D) allele. The Aurora
kinase A (AurkA)-inducible mouse model has been reported recently33. This model
was generated using the tetracycline-inducible single-copy transgenic
system59 and carries the M2-rtTA gene inserted within the Rosa26 allele
and a cassette containing the Aurora-A complementary DNA under the
control of the doxycycine-responsive promoter (tetO) inserted downstream
of the Col1a1 locus. The ﬁnal mouse model, Col1a1tetO-Aurka/þ ;
Rosa26rtTA/rtTA, overexpresses exogenous Aurora-A on doxycycline
treatment in a wide range of proliferative and non-proliferative tissues
and cells.
Both Aurora A mouse models were maintained in a mixed background (129/Sv,
CD1, C57BL/6J and FVB/N). Mice were housed in the pathogen-free animal facility
of the Centro Nacional de Investigaciones Oncolo´gicas (Madrid) in accordance
with the animal care standards of the institution. For experimentation, genotyped
littermates, male or female mice of 7–9 weeks were used. These animals were
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observed on a daily basis and sick mice were killed humanely in accordance with
the Guidelines for Humane Endpoints for Animals used in biomedical research. All
animal protocols were approved by the Instituto de Salud Carlos III Committee for
Animal Care and Research.
Mouse CD4þ T cells were obtained from single-cell suspensions of the spleen
and mesenteric lymph node. The cell suspensions were incubated with biotinylated
antibodies against CD8, CD16, CD19, CD24, CD117, MHC class II (I-Ab), CD11b,
CD11c and DX5, and were subsequently incubated with streptavidin microbeads
(MACS; Miltenyi Biotec). CD4þ T cells were negatively selected in an auto-MACS
Pro Separator (Miltenyi Biotec). Cells were then labelled with antibodies to CD4
and CD25, and analysed by ﬂow cytometry to conﬁrm their purity and resting
status. For conditional KO and knockin studies, mouse CD4þ T cells were
cultured with tamoxifen for 96 h (Aurora A gene deletion model) or doxycycline
for 20 h (Aurora A overexpression model) in RPMI 1640þGlutaMAX–Iþ 25mM
HEPES (Gibco–Invitrogen) supplemented with 10% fetal bovine serum
(Hyclone, Thermoﬁsher), 50 IUml 1 per ml penicillin, 50mgml 1 per ml
streptomycin and 5 ngml 1 per ml murine IL-7.
Antibodies and reagents. The antibodies used in this study were anti-CD3z Y83
(ab68236; 1:1,000 for WB), anti-LAT Y132 (ab4476; 1:1,000 for WB), anti-Aurora
A T288 (ab83968; 1:200 for immunoﬂuorescence (IF)) and anti-Aurora A (a13824;
[35C1]; 1:500 for WB) from Abcam; anti-a-Tubulin (T6199; clon DM1A; 1:2,000
for WB) and ﬂuorescein isothiocyanate-conjugated anti-a-Tubulin (F2168; clon
DM1A; 1:100 for IF) from Sigma; anti-ERK1/2 (SKU 13-6200; 1:500 for WB), anti-
V5 (R960-25; 1:1,000 for WB and 0.5 mg per point for IP) and anti-Src pY418 (44-
660G; that recognizes
Lck Y394 (ref. 34), 1:1,000 for WB) from Invitrogen; anti-ERK1/2 T202/Y204
(44285; 1:1,000 for WB) from Calbiochem; anti-Aurora A (04-1037; 1:1,000 for
WB) and anti-Lck (05-435; 1 mg per point for IP) from Millipore; anti-PKCy
(610090; 1:1,000 for WB), anti-Rac1 (610651; 1:1,000 for WB), anti-mouse
CD3e (553057; clon 2C11; 10 mgml 1) and CD28 (553294; 5 mgml 1) and
anti-human CD28 (555725; 2 mgml 1) from BD Pharmingen; anti-human CD3e
(317302; clon OKT3; 1:200 for IF) from BioLegend; anti-PKCy T538 (9377S;
1:1,000 for WB), anti-PLCg1 (2822S; 1:1,000 for WB), anti-PLCg1 Y783 (#2821L;
1:1,000) and anti-Lck (2752; 1:1,000 for WB and 1:200 for IF) from Cell Signaling
Tech; anti-PKCy (sc-1875; 1:200 for IF) and anti-LAT (sc-7948; 1:500 for WB)
from Santa Cruz. The anti-human CD3e (300314; HIT3a; 5 mgml 1) was from
eBioscience. The anti-human-CD3z and anti-GST antibodies were produced in
Dr B. Alarco´n’s laboratory (Centro de Biologı´a Molecular Severo Ochoa, Madrid).
Goat anti-Armenian hamster IgG was from Jackson ImmunoResearch (127-005-
160; 10 mgml 1). Cell tracker CMAC (7-amino-4-chloromethylcoumarin; C2110,
0.1 mM) was from Molecular Probes–Invitrogen. Enterotoxins E (SEE; 0.3 mgml 1)
and B (SEB; 5mgml 1) from Staphylococcus aureus were purchased from Toxin
Technologies; the HA peptide (200 mgml 1) was synthesized by Lifetein LLC.
Recombinant human Lck, histidine tagged was from MBL (RB-P3043). The Aurora
A inhibitor MLN8237 and Aurora B inhibitor AZD1152 were from Selleckchem.
Prolong Gold anti-fade mounting medium (P-36934), phalloidin conjugated to
Alexa Flour 647 (A-22287; 1:100 for IF), goat anti-rabbit and goat anti-mouse
highly cross-adsorbed secondary antibodies conjugated to Alexa Fluor 488
(A-11034 and A-11029, respectively; 1:500 for IF), 568 (A11036 and A-11031,
respectively; 1:500 for IF) or 647 (A-21443 and A-21236, respectively; 1:500 for IF),
donkey anti-goat highly cross-adsorbed secondary antibody conjugated to Alexa
Fluor 647 (A-21447; 1:500 for IF) and donkey anti-rabbit secondary antibody
conjugated to Alexa Flour 555 (A-31572; 1:500 for IF) were from Thermoﬁsher
Scientiﬁc. Fibronectin and Poly-L-Lys were from Sigma. Horseradish
peroxidase-conjugated secondary antibodies for WB (anti-rabbit 31460, mouse
31430 or goat IgGþ IgM 31460) were from Pierce–Thermoﬁsher Scientiﬁc. Murine
IL-7 was from PreproTech (217-17).
Plasmids and siRNAs and transfection. The plasmid encoding GFP-EB3 was
generously provided by Dr A. Akhmanova (Utrecht University, Utrecht, The
Netherlands)24. The plasmids encoding WT or KD Aurora A-GFP and WT or
KD V5-Aurora A were reported previously60. CD4-Lck38 in pRC3.1 plasmid was
sub-cloned in the laboratory of Dr M Alonso; Dr M Alonso also provided the
Lck-GFP39 and CD4DCyt-GFP40 constructs (CBM, Madrid, Spain), and
Actin–mCherry-expressing CH7C17 T-cell clones were generated in the laboratory
of Dr JM Serrador (CBM). The GST-PAK-CD (p21-activated kinase-CRIB-
Domain)30 was generously provided by Dr Collard (NKI, Amsterdam, The
Netherlands). The plasmid pGEX2TK (Pharmacia) was used as control. T-cell lines
were transfected with speciﬁc double-stranded siRNA against human Aurora
Kinase A 30-untranslated region (50-CCCUCAAUCUAGAACGCUA-30)61 or
a scramble negative control (50-CUAGGGUGCCGAGUGUGUU-30). For
transfection, T-cell lines were centrifuged at 1,200 r.p.m. for 5min and washed with
Hank’s balance salt solution(HBSS); Lonza) and resuspended in Opti-Mem I
(Gibco–Invitrogen) (15 106 cells in 400 ml). Corresponding plasmids (10 mg) were
added to cell lines and transfection was performed with the gene-pulser III system
from Bio-Rad Laboratories (240V, 975mO, B27ms). After electroporation, cells
were cultured in 9ml RPMI 1640þGlutaMAXTM–Iþ 25mM HEPES medium.
After 4 h, 500 ml fetal bovine serum was added to the cell medium. Experiments
were performed 24 h after transfection. For mouse and human primary CD4þ
T cells, corresponding plasmids (10 mg) were added to cells and transfection was
performed with the Nucleofector I from Amaxa Biosystems (X-01). The plasmids
encoding Aurora A-V5 WT or KD (24 mg) were tranfected with Lipofectamine
(Invitrogen) in HEK293T cells. Experiments were performed 24 h after
transfection.
T cell activation and lysis for pull-down and immunoblotting. For human TCR
stimulation, T cells were incubated for the indicated times with latex microbeads
(6.4 mm diameter) conjugated to anti-CD3 antibody (10 mgml 1) and anti-CD28
antibody (5mgml 1). For mouse TCR stimulation, T cells were incubated with
anti-CD3 antibody (10 mgml 1) and anti-CD28 antibody (5mgml 1) for 15
(4 C) followed by incubation with goat anti-Armenian hamster IgG for 15min
(4 C). For antigen stimulation, Raji cells were pulsed with 0.3 mgml 1 SEE
(30min) and mixed with J77 or J.CAM1 cells (1:5); alternatively, Hom2 cells pulsed
with 200 mgml 1 HA peptide (2 h) or with 5 mgml 1 SEB (30min) and were
mixed with CH7C17 cells (1:5) in HBSS. Where indicated, cells were pretreated
with MLN8237 (10 mM) or AZD1152 (100 nM), or vehicle for 45min at 37 C in
HBSS before stimulation with the corresponding APC or anti-CD3 and anti-CD28
antibodies. Cells were centrifuged at low speed for the indicated times at 37 C to
favour the formation of conjugates. Cells were lysed in 5mM Tris-HCl pH 7.5
containing 1% NP40, 0.2% Triton X-100, 150mM NaCl, 2mM EDTA, 1.5mM
MgCl2, and phosphatase and protease inhibitors. Lysates were spin at 14,000 r.p.m.
(4 C, 10min) to remove debris and nuclei. For GST-Nck or GST-PAK-CD,
pull-down assay experiments were performed as described previously28,30. Proteins
were resolved by SDS–PAGE and transferred to nitrocellulose membranes. After
blocking with TBS containing 0.2% TWEEN and 5% BSA, membranes were blotted
with primary antibodies (o/n at 4 C) and peroxidase-labelled secondary antibodies
(30min), and detected with the ImageQuant LAS-4000 chemiluminiscence and
ﬂuorescence imaging system (Fujiﬁlm). Source images from relevant WB are
available in the Supplementary Figs 6–9.
Cell conjugate and IF and IS analysis. Raji B cells or Hom2 B cells were washed
once with HBSS and loaded with the CMAC cell tracker (10mM) and with SEE or
SEB for 30min or HA peptide for 2 h at 37 C. T cells (1 105 cells) were mixed
with the corresponding APC (1:1) and plated onto Poly-L-Lys-coated slides
(50 mgml 1; 1 h at 37 C). Cells were allowed to settle for 20min at 37 C, ﬁxed
with 4% paraformaldehyde and 0.12mM sucrose in PHEM (60mM PIPES, 25mM
Figure 9 | Aurora controls localization and phosphorylation of the tyrosine kinase Lck. (a) Maximum Z projection of XYZ stack of human Jurkat T cells
pretreated with vehicle (DMSO) or Aurora A inhibitor (MLN8237) and conjugated with SEE-preloaded Raji B cells (APCs; 30min). Cells were ﬁxed and
stained for a-tubulin–ﬂuorescein isothiocyanate (FITC) (green), PKCy (magenta) and Lck (red). Bright-ﬁeld images are included. Scale bar, 10mm.
(b) Quantiﬁcation of Lck accumulation at the IS in conjugates as in a from three independent experiments (DMSO, n¼ 96. MLN8237, n¼ 94). Data
represent means±s.d. Means were compared with a t-test; ****Po0.0001. (c) Immunoblotting of Lck phosphorylation at Y394 in primary human CD4þ
Tcells. Cells were pretreated with DMSO or MLN8237 and conjugated for the indicated times with anti-CD3/CD28-coated beads. Total Lck and actin are
included as loading controls. Arrows point Lck band. (d) Quantiﬁcation of data from four independent experiments as in c. Error bars represent s.d. Medians
were compared with a Friedman test (*Po0.05). (e) Immunoblots of CD3z phosphorylation in lysates of J.CAM1 Tcells transfected with Lck-GFP, CD4-Lck
or CD4-DCyt-GFP, pretreated with DMSO or MLN8237 and conjugated for 5min with SEE-pulsed APCs. (f) T-cell lymphoblasts pretreated with DMSO or
MLN8237 were activated or not with SEE-pulsed APCs (2min) and subjected to IP using an anti-Lck antibody. The immunoprecipitates were subjected to
MS analysis. Upper panel, MS/MS extracted ion chromatograms of the Y394-phosphorylated and non-modiﬁed forms of Lck peptide LIEDNEYTAR. Lower
panel, phosphorylated:non-modiﬁed peak ratios. (g) Recombinant Lck was incubated with Aurora A WT (in the absence or presence of MLN8237) or
Aurora A KD immunoprecipitated from nocodazole-treated (16 h), transfected HEK293 cells. Lck and Aurora were incubated for 30min in the presence of
ATP and the mixture analysed by MS. Upper panel, MS/MS extracted ion chromatograms of the Y394-phosphorylated and non-modiﬁed forms of Lck
peptide LIEDNEYTAR. Lower panel, phosphorylated:non-modiﬁed peak ratios. See Supplementary Table 1 for representative MS/MS spectra of the
phosphorylated and non-phosphoryated forms of the peptide at the peaks.
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Hepes, 5mM EGTA and 2mM MgCl2), and permeabilized for 5min at room
temperature with 0.2% Triton X-100 in immunoﬂuorescence solution (PHEM
containing 3% BSA, 100 mgml 1 g-globulin and 0.2% azide). Cells were blocked
for 30min with immunoﬂuorescence solution and stained with the indicated pri-
mary antibodies (5mgml 1) followed by Alexa Fluor 488-, 568- or 647-labelled
secondary antibodies, Alexa-conjugated phalloidin (5 mgml 1) or ﬂuorescein
isothiocyanate-conjugated anti-a-tubulin (0.1mgml 1). Cells were mounted on
Prolong Gold and analysed with a Leica SP5 confocal microscope (Leica) ﬁtted
with a HCX PL APO  63/1.40–0.6 oil objective and images were processed and
assembled using Image J software (http://rsbweb.nih.gov/ij/) and Photoshop soft-
ware. For quantiﬁcation in individual ISs, we used a home-made plugin for Image J
software (http://rsbweb.nih.gov/ij/) called ‘Synapse Measures’. By comparing
ﬂuorescence signals from multiple regions of the T cell, APC, IS and background
ﬂuorescence, the programme yields accurate measurements of localized
immunoﬂuorescence. A detailed description of Synapse Measures including the
algorithms used is described62.
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IP and MS and phosphorylation. For Lck IP assay, human lymphoblast pretreated
with MLN8237 (10mM) or vehicle (DMSO) for 30min were activated with Raji
preloaded with SEE for 2min at 37 C. Next, cells were lysated for 40min at 4 C in
extraction buffer with 5mM Tris-HCl pH 7.5 containing 0.5% NP40, 150mM
NaCl, 2mM EDTA, 1.5mM MgCl2, and phosphatase and protease inhibitors.
Lysates were spun at 14,000 r.p.m. (4 C, 10min) to remove debris and nuclei. The
anti-Lck antibody was allowed to bind with Protein G-conjugated sepharose beads
(GE Healthcare) overnight at 4 C and then mixed with the extracts. The mixture
was left in agitation at 4 C for 2 h and then beads were washed ten times with the
same buffer used for lysate without detergents. As a control, we used beads
preincubated with the extracts. For Aurora A IP, V5-Aurora A WT- or
KD-transfected HEK293T cells were lysated with RIPA buffer, with 1% Triton
X-100, 0.5% deoxycholate (Sigma-Aldrich), 0.1% SDS in Tris buffer saline and
sonicated (3 30 s pulses). The anti-V5 antibody was mixed with the extracts and
left in agitation at 4 C for 2 h, and then Protein G-conjugated sepharose (GE
Healtcare) was added for 1 h in agitation at 4 C. Beads were washed three times
with the buffer kinase with 20mM Hepes pH 7.4 containing 150mM KCl, 10mM
MgCl2, 1mM EGTA, 0.5mM dithiothreitol, and phosphatase and protease
inhibitors, and once with buffer kinase plus NaCl 0.5mM. Beads were incubated
with 0.5 mg of recombinant Lck in buffer kinase plus 10mM ATP during 30min at
30 C. For proteomic analysis, the samples were trypsin-digested using the whole
proteome in-gel digestion protocol63. The peptides produced by digestion were
vacuum dried and redissolved in 1% triﬂuoroacetic acid for desalting in
reversed-phase C-18 extraction cartridges (Oasis, Waters Corporation, Milford,
MA, USA). High-resolution parallel reaction monitoring of phosphorylated
peptides was carried out on an Easy nLC 1000 nano-HPLC apparatus (Thermo
Scientiﬁc, San Jose, CA, USA) coupled to a hybrid linear ion trap-orbitrap
(Orbitrap Elite, Thermo Scientiﬁc). Peptides were suspended in 0.1% formic acid
and then loaded onto a C-18 reversed-phase nano-column (75 mm I.D., 50 cm) and
separated in a continuous gradient consisting of 8–30% B for 15min and 30–90% B
for 2min (B¼ 90% acetonitrile, 0.1% formic acid) at 200 nlmin 1. Peptides were
ionized using a Picotip emitter nanospray needle (New Objective, Woburn, MA,
USA). Each MS run consisted of enhanced FT-resolution spectra (30,000
resolution) in the 390–1,600m/z range followed by data-independent MS/MS
spectra of 11 parent ions acquired along the chromatographic run. The AGC target
value in the Orbitrap for the survey scan was set to 1,000,000. Fragmentation in the
linear ion trap was performed at 35% normalized collision energy with a target
value of 10,000 ions and the dynamic exclusion was set to 0.5min. Data analysis
was performed with Xcalibur 2.2 (Thermo Scientiﬁc).
Time-lapse confocal and TIRF movie microscopy. For cell conjugates, 3D
imaging was performed with CMAC-loaded Raji APCs (5 105; SEE-pulsed
(Jurkat cells), SEB-pulsed (CH7C17 cells) or unpulsed) and were allowed to adhere
to ﬁbronectin-coated coverslips in Attoﬂuor open chambers (Molecular
Probes–Invitrogen) at 37 C in a 5% CO2 atmosphere or in glass-bottom dishes
(No. 1.5 Mattek; Ashland, MA, USA). The cells were maintained in 1ml HBSS
(1% fetal bovine serum and 25mM HEPES). Cells were pretreated with the
MLN8237 inhibitor and maintained in its presence during imaging when needed.
T cells were added (1:1 ratio) and a series of ﬂuorescence and differential
interference contrast or bright-ﬁeld frames were captured using a TCS SP5 confocal
laser scanning unit attached to an inverted epiﬂuorescence microscope (DMI6000)
ﬁtted with an HCX PL APO  63/1.40–0.6 oil objective. Images were acquired and
processed with the accompanying confocal software (LCS; Leica) and Image J
software (http://rsbweb.nih.gov/ij/). For 3D imaging of MT growing, cells were
allowed to settle onto glass-bottom dishes coated with anti-CD3 (10 mgml 1) and
anti-CD28 (3 mgml 1) monoclonal antibodies speciﬁc for human or mouse T cells
and XYZ series were captured with the resonant scanner of the TCS SP5 confocal
(8,000Hz) each 1.2 s or 1.1 s. Cells were pretreated with the MLN8237 inhibitor
and maintained in its presence during imaging. For TIRF microscopy, T cells stably
expressing EB3-GFP or transfected with EB3-GFP and CD3x-mCherry were
allowed to settle onto glass-bottom dishes coated with anti-CD3 (10 mgml 1) and
anti-CD28 (3mgml 1). Cells were pretreated with the MLN8237 inhibitor and it
was maintained in the imaging medium during acquisition. Recording was initiated
3min after cells were plated and cells were visualized with a Leica AM TIRF MC M
system mounted on a Leica DMI 6000B microscope coupled to an Andor-
DU8285_VP-4094 camera ﬁtted with a HCX PL APO  100.0, 1.46 oil objective.
For mCherry–b-actin-expressing T cells, recording was initiated on addition of
cells to the glass-bottom dishes. Images were processed with the accompanying
confocal software (LCS; Leica). The laser penetrance used was 150 or 200 nm for
both laser channels (488 and 561 nm), using the same objective angle. Time-lapse
settings were optimized for each type of experiment and are speciﬁed throughout
the text. Synchronization was performed with the accompanying Leica software
and images were processed with Leica software, Matlab and Image J software
(http://rsbweb.nih.gov/ij/).
Quantitative real-time PCR. Reverse transcriptase–PCR was performed with 1 mg
of RNA isolated with Trizol RNA reagent (Invitrogen) from CD4þ T cells
obtained from healthy donors. mRNA levels of IL-2, CD25 and CD69 were
determined in triplicate using the Power SYBR Green PCR master mix obtained
from Applied Biosystems (Warrington, UK). Expression levels were normalized to
the expression of glyceraldehyde-3-phosphate dehydrogenase. Primer sequences
are listed in Supplementary Table 2.
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